Western Magnesium (MLYF) 10-K 14 Feb 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Oct. 31, 2021	Jan. 31, 2022	Apr. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--10-31
Entity File Number	000-56323
Entity Registrant Name	WESTERN MAGNESIUM CORPORATION
Entity Central Index Key	0001801762
Entity Tax Identification Number	61-1934413
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8180 Greensboro Drive
Entity Address, Address Line Two	Suite 720
Entity Address, City or Town	McLean
Entity Address, State or Province	VA
Entity Address, Country	US
Entity Address, Postal Zip Code	22102
City Area Code	(571)
Local Phone Number	378-0762
Title of 12(b) Security	Common Stock, $0.001 par value
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 31,641,937
Entity Common Stock, Shares Outstanding		421,871,770
ICFR Auditor Attestation Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Current assets
Cash	$ 462,360	$ 39,571
Amounts receivable	151,485	4,579
Prepayments	133,647	115,109
Deposits held by related parties	486,462
Total Current assets	1,233,954	159,259
Non-current assets
Property, plant and equipment	2,574,704	79,436
Right-of-use assets	598,575	373,987
Mineral property costs	93,453	93,453
Reclamation deposits	2,826	2,628
Other deposits	10,000
TOTAL ASSETS	4,513,512	708,763
Current liabilities
Accounts payable and accrued liabilities	1,989,316	1,169,817
Due to related parties	1,026,817	843,990
Lease obligations – current	192,045	143,709
Promissory note		60,567
Provision for flow through share issuances	233,285	216,924
Convertible debenture	107	96,318
Convertible debenture – derivative liability	7,449,700	20,123
Total Current liabilities	10,891,270	2,551,448
Non-current liabilities
Lease obligations – non-current	392,280	237,218
Total liabilities	11,283,550	2,788,666
Shareholders’ deficit
Capital stock Authorized: 1 billion common stock at par value of $0.001 Issued and paid: 392,943,398 (2020 – 323,419,527)	29,842,167	21,322,022
Additional paid-in-capital	15,186,480	4,182,037
Obligations to issue shares	209,827	596,872
Accumulated other comprehensive income	121,109	399,175
Deficit	(52,129,621)	(28,580,009)
Total shareholders’ deficit	(6,770,038)	(2,079,903)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$ 4,513,512	$ 708,763

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Oct. 31, 2021$ / sharesshares	Oct. 31, 2020$ / sharesshares
Statement of Financial Position [Abstract]
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Par or Stated Value Per Share | (per share)	$ 0.001	$ 0.001
Common Stock, Shares, Issued	392,943,398	323,419,527
Common Stock, Shares, Outstanding	392,943,398	323,419,527

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Expenses (recoveries)
Bank charges	$ 15,287	$ 10,764
Computer system and software	94,426	58,230
Consulting and management fees	914,617	598,574
Depreciation	229,902	86,706
Due diligence expenses	5,565	25,776
Engineering expenses	105,706	569,145
Foreign exchange gain	(109,054)	(10,685)
Interest and accretion	74,319	60,638
Investor relations	280,249	237,874
Legal and professional fees	889,175	138,916
Office and general	180,348	185,553
Property maintenance fees	15,069	15,098
Facilities and rent	187,832	50,304
Salaries and benefits	3,168,008	1,797,783
Stock-based compensation	11,051,124	666,259
Shareholder communications	127,747	54,554
Subsidies and recoveries	(41,735)
Transfer agent and regulatory fees	107,098	64,371
Travel expenses	409,528	104,880
Costs and Expenses	17,705,211	4,714,740
Other items
Change in fair value of derivative liability	(5,701,270)	4,979
Loss on recognition of debt host liability	(140,943)
Gain on sale of assets previously written off		37,156
Write-off of equipment	(2,188)
Nonoperating Income (Expense)	(5,844,401)	42,135
Net loss for the year	(23,549,612)	(4,672,605)
Other comprehensive loss
Foreign currency translation	(278,066)	(76,806)
Comprehensive loss for the year	$ (23,827,678)	$ (4,749,411)
Basic and diluted loss per common share	$ (0.07)	$ (0.01)
Weighted average number of common shares outstanding – basic and diluted	356,656,854	312,450,631

Consolidated Statements of Shar

Consolidated Statements of Shareholders Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Obligation to issue shares [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Oct. 31, 2019	$ 18,587,118	$ 3,535,553	$ 39,722	$ 475,981	$ (23,907,404)	$ (1,269,030)
Beginning balance, shares at Oct. 31, 2019	278,939,075
Shares issued pursuant to private placements [note 14[b]]	$ 416,719		(39,722)			376,997
Shares issued pursuant to private placements, shares	3,643,791
Shares issued on warrants exercised [note 14[b]]	$ 2,313,284					2,313,284
Shares issued on warrants exercised, shares	40,336,661
Shares issued on options exercised [note 14[b]]	$ 46,176	(19,775)				26,401
Shares issued on options exercised, shares	500,000
Share issue costs [note 14[b]]	$ (41,275)					(41,275)
Stock-based compensation [note 14[d]]		666,259				666,259
Share subscriptions [note 14[f]]			596,872			596,872
Foreign currency translation				(76,806)		(76,806)
Net loss for the year					(4,672,605)	(4,672,605)
Ending balance, value at Oct. 31, 2020	$ 21,322,022	4,182,037	596,872	399,175	(28,580,009)	(2,079,903)
Ending balance, shares at Oct. 31, 2020	323,419,527
Shares issued pursuant to private placements [note 14[b]]	$ 7,438,041		(596,872)			6,841,169
Shares issued pursuant to private placements, shares	56,979,482
Shares issued on warrants exercised [note 14[b]]	$ 891,811	(4,291)				887,520
Shares issued on warrants exercised, shares	7,014,969
Shares issued on options exercised [note 14[b]]	$ 262,666	(121,932)				140,734
Shares issued on options exercised, shares	2,630,000
Shares issued for convertible debenture [notes 13[a] and 14[b]]	$ 162,829					162,829
Shares issued for convertible debenture, shares	1,360,959
Shares issued for equipment [note 14[b]]	$ 305,832					305,832
Shares issued for equipment, shares	1,538,461
Share issue costs [note 14[b]]	$ (541,034)					(541,034)
Stock-based compensation [note 14[d]]		11,051,124				11,051,124
Equity component of convertible debenture [note 13[b]]		79,542				79,542
Share subscriptions [note 14[f]]			209,827			209,827
Foreign currency translation				(278,066)		(278,066)
Net loss for the year					(23,549,612)	(23,549,612)
Ending balance, value at Oct. 31, 2021	$ 29,842,167	$ 15,186,480	$ 209,827	$ 121,109	$ (52,129,621)	$ (6,770,038)
Ending balance, shares at Oct. 31, 2021	392,943,398

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
OPERATING ACTIVITIES
Net loss for the year	$ (23,549,612)	$ (4,672,605)
Add (subtract) items not affecting cash:
Accrued interest and accretion	25,331	53,605
Change in fair value of derivative liability	5,701,270	(4,979)
Loss on recognition of debt host liability	140,943
Depreciation of property, plant and equipment	44,148	20,871
Depreciation of right-of-use assets	185,754	65,835
Foreign exchange gain	(198,371)	(55,080)
Gain on sale of exploration and evaluation assets		(37,156)
Interest expense on lease obligations	25,319	7,033
Stock-based compensation	11,051,124	666,259
Write-off of equipment	2,188
Changes in non-cash working capital items relating to operations:
Amounts receivable	(144,283)	15,500
Prepayments	(9,703)	(35,317)
Deposits held by related parties	(478,902)
Accounts payable and accrued liabilities	719,906	510,773
Due to related parties	117,321	194,727
Cash used in operating activities	(6,367,567)	(3,270,534)
INVESTING ACTIVITIES
Purchase of property, plant and equipment	(2,056,566)	(18,172)
Other deposits	(10,000)
Proceeds from sale of exploration and evaluation assets		37,157
Cash provided by (used in) investing activities	(2,066,566)	18,985
FINANCING ACTIVITIES
Proceeds from issuance of shares, net of share issuance costs	7,328,389	2,715,129
Proceeds from share subscriptions	209,827	557,150
Proceeds from convertible debenture	1,579,542	111,470
Payments of promissory note	(65,761)	(56,478)
Payments of lease obligations	(201,562)	(69,448)
Cash provided by financing activities	8,850,435	3,257,823
Change in cash for the year	416,302	6,274
Cash, beginning of the year	39,571	33,649
Effect of foreign exchange on cash	6,487	(352)
Cash and cash equivalents, end of the year	462,360	39,571
Other non-cash transactions:
Shares issued for conversion of debt and equipment	468,661
ROU asset addition by way of lease obligation	351,886	437,812
Other cash flow disclosures:
Cash paid during the period for interest	$ 13,204	$ 28,199

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN	12 Months Ended
	Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND GOING CONCERN	1. NATURE OF OPERATIONS AND GOING CONCERN Western Magnesium Corporation (the “Company”, or “WMC”) was incorporated under the laws of British Columbia on March 24, 1966. On May 14, 2019, the Company discontinued from the jurisdiction of the Business Corporations Act (British Columbia) and domesticated under the General Corporation Law of the State of Delaware under the name “Western Magnesium Corporation”. The Company is a reporting issuer in Canada and in the United States, listed for trading in Canada on the TSX Venture Exchange (the “TSX-V”) under the symbol “WMG.V”, in the United States on the OTCQB tier of the OTC Markets (the “OTCQB”) under the symbol “MLYF”, and in Germany on the Frankfurt Stock Exchange under the symbol “3WM”. The Company has developed proprietary magnesium production technology with the aim of becoming a premier low-cost producer of green primary magnesium metal. As at October 31, 2021, the Company had an accumulated deficit of $ 52,129,621 28,580,009 9,657,316 2,392,189 23,827,678 4,749,411 These consolidated financial statements (the “Financial Statements”) have been prepared under the assumption that the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will be able to meet its obligations and continue its operations for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Management believes that the going concern assumption is appropriate for these Financial Statements based on its continuing ability to raise financings through share and debt issuances. If future financing is unavailable or if for any reason the Company is unable to continue as a going concern, it could impact the Company’s ability to realize its assets at their recognized values and to meet its obligations in the ordinary course of business at the amounts stated in these Financial Statements. These Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern. If the going concern assumption is not used, the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these Financial Statements. These factors indicate the existence of a material uncertainty that cast substantial doubt on the Company’s ability to continue as a going concern. In March 2020, the World Health Organization declared COVID-19 a global pandemic. In order to combat the spread of COVID-19, governments worldwide, including the Unites States and Canada, have enacted emergency measures including travel bans, legally enforced or self-imposed quarantine periods, social distancing and business and organization closures. These measures have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. The impact on the Company has not been significant but could affect the Company’s ability to raise financings in the future and restrict travel. Management continues to monitor the situation. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

BASIS OF PRESENTATION

BASIS OF PRESENTATION	12 Months Ended
	Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION These Financial Statements comprise the financial statements of Western Magnesium Corporation and its wholly owned subsidiaries, Western Magnesium Canada Corporation, incorporated in British Columbia, Canada and Western Magnesium Corp., incorporated in the State of Nevada in the United States. [a] Accounting standards The accompanying Financial Statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) on the basis that the Company will continue as a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for the next year. Realization values may be substantially different from carrying values as shown and these Financial Statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. These Financial Statements have been prepared on a historical cost basis except for financial instruments that have been measured at fair value. In addition, these Financial Statements have been prepared using the accrual basis of accounting, except for cash flow information. [b] Functional and presentation currency These Financial Statements are presented in United States dollars (“US dollars” or “USD”), except where otherwise indicated. The functional currency of each entity of the Company is as follows: Entity Functional Currency Western Magnesium Corporation Canadian dollars (“CA$”) Western Magnesium Canada Corporation Canadian dollars Western Magnesium Corp. United States dollars The accounts of the Company, and those of its subsidiary Western Magnesium Canada Corporation, have been translated to US dollars. [c] Critical accounting estimates and judgments Significant Estimates and Assumptions The preparation of these Financial Statements in accordance with US GAAP requires the Company to make estimates and assumptions concerning the future. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Estimates and assumptions where there is potential risk of material adjustments to assets and liabilities in future accounting periods include the useful lives of property, plant and equipment, the recoverability of the carrying value of exploration and evaluation assets, fair value measurements for financial instruments, discount rates for leases, the recoverability and measurement of deferred tax assets and liabilities and contingent liabilities. Significant Judgments The preparation of these Financial Statements in accordance with US GAAP requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s Financial Statements include: - the assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to substantial doubt; - whether there are indicators of impairment of the Company’s exploration and evaluation assets and other non-current assets; - the classification of financial instruments; and - determination of functional currency. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Oct. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	3. SIGNIFICANT ACCOUNTING POLICIES The accounting policies set out below have been applied consistently to all periods presented in these Financial Statements by the Company and its subsidiaries. [a] Principles of consolidation These Financial Statements include the accounts of the Company and its wholly owned and controlled subsidiaries as described in note 2 [b] Foreign currency Items included in the financial statements of each consolidated entity are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Foreign currency transactions are translated into the functional currency using the prevailing exchange rates on the dates of transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statements of loss and comprehensive loss. Assets and liabilities of the Company and its subsidiary with a functional currency in Canadian dollars are translated at the period end rates of exchange, and the results of its operations are translated at average rates of exchange for the period. Equity transactions have been translated using historical rates in effect on the date that each transaction occurred. The resulting translation adjustments are included in accumulated other comprehensive income or loss as shareholders’ equity or deficit. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive income or loss. [c] Cash and cash equivalents Cash and cash equivalents include highly liquid financial instruments that are readily convertible into cash with original maturities of three months or less. [d] Property, plant and equipment Property, plant and equipment (“PP&E”) is carried at cost, less accumulated depreciation and accumulated impairment losses. The cost of an item of PP&E consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. Depreciation is provided at rates calculated to write off the cost of PP&E, less their estimated residual value. The depreciation rates and method applicable to each category of property, plant and equipment are as follows: SCHEDULE OF DEPRECIATION RATE Class Rate Computer equipment 55% declining balance Furniture 20% declining balance Plant equipment 20% declining balance Furnace To be determined Leasehold improvement Term of lease Right-of-use assets Term of lease WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated An item of PP&E is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in profit or loss in the consolidated statements of loss and comprehensive loss. Where an item of PP&E comprises major components with different useful lives, the components are accounted for as separate items. Expenditures incurred to replace a component of an item of PP&E that is accounted for separately, including major inspection and overhaul expenditures, are capitalized. [e] Reclamation deposits The Company maintains cash deposits, as required by regulatory bodies, as assurance for the funding of decommissioning costs. These funds are restricted to that purpose and are not available to the Company until the reclamation obligations have been fulfilled and are therefore classified as long-term assets. [f] Research and development Expenditures on research activities taken to develop a pyro metallurgical process to extract and recover magnesium metal from dolomite are expensed as incurred. Development expenditures are expensed in the period incurred. [g] Mineral property acquisition and exploration assets Mineral property acquisition costs are capitalized when incurred. Acquisition costs include cash consideration and the fair market value of shares issued on the acquisition of mineral property claims. Costs related to the development of mineral reserves are capitalized when it has been determined an ore body can be economically developed. The development stage begins when an ore body is determined to be economically recoverable based on proven and probable reserves and appropriate permits are in place, and ends when the production stage or exploitation of reserves begins. Major mine development expenditures are capitalized, including primary development costs such as costs of building access ways, tailings impoundment, development of water supply and infrastructure developments. Exploration costs include those relating to activities carried out (a) in search of previously unidentified mineral deposits, or (b) at undeveloped concessions. Pre-development activities involve costs incurred in the exploration stage that may ultimately benefit production that are expensed due to the lack of evidence of economic development, which is necessary to demonstrate future recoverability of these expenses. Secondary development costs are incurred for preparation of an ore body for production in a specific ore block or work area, providing a relatively short-lived benefit only to the mine area they relate to, and not to the ore body as a whole. All exploration costs have been expensed. Once production has commenced, capitalized costs will be depleted using the units-of-production method over the estimated life of the proven and probable reserves. If mineral properties are subsequently abandoned or impaired, any capitalized costs will be charged to the consolidated statements of loss and comprehensive loss in that period. The carrying cost of mineral properties is assessed for impairment whenever information or circumstances indicate the potential for impairment. Such evaluations compare estimated future net cash flows with carrying costs and future obligations on an undiscounted basis. If it is determined that the future undiscounted cash flows are less than the carrying value of the property, a write down to the estimated fair value is charged to the consolidated statements of loss and comprehensive loss for the period. Where estimates of future net cash flows are not available and where other conditions suggest impairment, management assesses if the carrying value can be recovered. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated Management conducted an impairment test on its mineral properties for recoverability and impairment loss during the years ended October 31, 2021 and 2020 and determined that its mineral properties were not impaired. For significant development projects, interest is capitalized as part of the historical cost of developing and constructing assets in accordance with ASC 835-20. Interest is capitalized until the asset is ready for service. Capitalized interest is determined by multiplying the Company’s weighted-average borrowing cost on general debt by the average amount of qualifying costs incurred. Once an asset subject to interest capitalization is completed and placed in service, the associated capitalized interest is expensed through depletion or impairment. [h] Impairment of non-financial assets Non-financial assets are evaluated at the end of each reporting period by management for indicators that carrying value is impaired and may not be recoverable. When indicators of impairment are present, non-financial assets are tested for impairment as an individual asset, as part of an asset group or at the reporting unit (“RU”) level. An asset group is the lowest level for which there are identifiable cash flows (i.e. both cash inflows and cash outflows) that are largely independent of the net cash flows of other groups of assets. An RU is an operating segment or one level below an operating segment if certain conditions are met. Impairment tests for non-financial assets subject to depreciation or amortization are applied to individual assets if possible. If this is not possible, then these assets are tested for impairment at the asset group level. An impairment loss is triggered for non-financial assets only if the asset’s, or asset group’s, carrying amount exceeds its recoverable amount (i.e. the carrying amount is greater than the undiscounted cash flows of the asset or asset group). If the carrying amount is not recoverable, then the impairment loss is the difference between the carrying amount of the asset (asset group) and the fair value of the asset (asset group). An impairment loss for an asset group is allocated pro rata to the non-financial assets in the asset group. Impairment losses are recognized in the consolidated statements of loss and comprehensive loss and are not reversed. [i] Income taxes The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company has adopted the provisions of FASB ASC 740 “Income Taxes” regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of loss and comprehensive loss. When applicable, the Company classifies penalties and interest associated with uncertain tax positions as a component of income tax expense in its consolidated statements of loss and comprehensive loss. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [j] Loss per share Basic earnings (loss) per share (“EPS”) is calculated by dividing profit or loss attributable to ordinary equity holders (numerator) by the weighted average number of ordinary shares outstanding (denominator) during the period. The denominator is calculated by adjusting the shares issued at the beginning of the period by the number of shares bought back during the period, multiplied by a time-weighting factor. Diluted EPS is calculated by adjusting the earnings and number of shares for the effects of dilutive options and other dilutive potential units. The effects of anti-dilutive options and potential units are ignored in calculating diluted EPS. All options and potential units are considered anti-dilutive when the Company is in a loss position. [k] Share-based payments The Company has an equity-settled share purchase stock option plan that is described in note 14 The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity-based instruments. The cost of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. The Company accounts for the granting of stock options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all stock options is expensed over their vesting period with a corresponding increase to additional paid-in capital. Compensation costs for stock-based payments that do not include performance conditions are recognized on a straight-line basis. Compensation cost associated with a share-based award having a performance condition is only recognized over the requisite service period if it is probable. Share-based awards with a performance condition are accrued on an award by award basis. The share-based compensation fair value is determined using an estimated forfeiture rate. Compensation ultimately recognized is revised in subsequent periods to reflect final grant amounts. For employees and consultants who are working on specific capital projects, the share-based compensation is allocated to projects under development. For the remainder of employees and consultants, the compensation is expensed. [l] Decommissioning liabilities The Company records a liability for the reclamation of its exploration and evaluation interests based on the best estimate of costs for site closure and reclamation activities that the Company is legally or constructively required to remediate, and the liability is recognized at the time the environmental disturbance occurs. The resulting costs are capitalized to the corresponding asset. The fair value of the provision for closure and reclamation liabilities is estimated using expected cash flows, based on engineering and environmental reports prepared by third party industry specialists, discounted at a pre-tax rate specific to the liability. The capitalized amount is amortized on the same basis as the related asset. The liability is adjusted for accretion of the discounted obligation and any changes in the amount or timing of the underlying future cash flows. Significant judgments and estimates are involved in forming expectations of the amount and timing of future site closure and reclamation cash flows. Future restoration costs are reviewed annually and any changes in the estimate are reflected in the present value of the provision at the reporting date. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [m] Share capital The Company records proceeds from share issuances net of issuance costs. Shares issued for consideration other than cash are valued at the quoted price on the date the shares are issued. [n] Financial instruments The Company’s classification of its financial instruments is as follows: Asset or Liability Classification Cash Held-for-trading Amounts receivable Amortized cost Accounts payable Amortized cost Due to related parties Amortized cost Promissory note and convertible debenture Amortized cost Derivative liability Fair value through profit and loss (“FVTPL”) The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Observable inputs other than Level I, quoted prices for similar assets or liabilities in active prices whose inputs are observable or whose significant value drivers are observable; and Level 3: Assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s derivative liability is based on Level 3 inputs in the ASC 820 fair value hierarchy. . Derivative Liabilities The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Oct. 31, 2021
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	4. RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Standards Adopted During the Year Fair Value Measurements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” which adds the disclosure of the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. Certain alternatives apply. Effective November 1, 2020, the Company adopted the new standard. There was no material impact or adjustment to these Financial Statements. New Accounting Standards Not Yet Adopted There are no new accounting standards not yet adopted by the Company that are expected to have a significant impact on its Financial Statements.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Oct. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	5. PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Computer Equipment Furniture Leasehold Improvement Furnace & Plant Equipment Total $ $ $ $ $ Cost Balance, October 31, 2019 22,632 33,584 5,850 27,897 89,963 Additions 9,852 5,672 1,810 838 18,172 Foreign exchange effect (166 ) (340 ) (50 ) (322 ) (878 ) Balance, October 31, 2020 32,318 38,916 7,610 28,413 107,257 Cost, Beginning Balance 32,318 38,916 7,610 28,413 107,257 Additions 77,955 11,510 129,257 2,278,205 2,496,927 Write-off of equipment (4,245 ) – – – (4,245 ) Foreign exchange effect 3,601 3,116 2,614 38,108 47,439 Balance, October 31, 2021 109,629 53,542 139,481 2,344,726 2,647,378 Cost, Ending Balance 109,629 53,542 139,481 2,344,726 2,647,378 Accumulated Depreciation Balance, October 31, 2019 3,184 1,679 1,950 – 6,813 Depreciation expense 11,412 6,598 2,861 – 20,871 Foreign exchange effect 81 49 7 – 137 Balance, October 31, 2020 14,677 8,326 4,818 – 27,821 Accumulated Depreciation, Beginning Balance 14,677 8,326 4,818 – 27,821 Depreciation expense 13,907 7,443 8,827 13,971 44,148 Write-off of equipment (2,057 ) – – – (2,057 ) Foreign exchange effect 1,294 745 502 221 2,762 Balance, October 31, 2021 27,821 16,514 14,147 14,192 72,674 Accumulated Depreciation, Ending Balance 27,821 16,514 14,147 14,192 72,674 Net Book Value Balance, October 31, 2020 17,641 30,590 2,792 28,413 79,436 Balance, October 31, 2021 81,808 37,028 125,334 2,330,534 2,574,704 Net Book Value 81,808 37,028 125,334 2,330,534 2,574,704 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

RIGHT-OF-USE ASSETS

RIGHT-OF-USE ASSETS	12 Months Ended
	Oct. 31, 2021
Right-of-use Assets
RIGHT-OF-USE ASSETS	6. RIGHT-OF-USE ASSETS As at October 31, 2021, the right-of-use assets are leases for the Company’s corporate offices in Vancouver, British Columbia and McLean, Virginia, and its research and development pilot plant located in Burnaby, British Columbia. These leases terminate on March 31, 2023, February 28, 2025 and September 30, 2023, respectively. The lease for the Company’s office in Las Vegas, Nevada ended on May 31, 2021. SCHEDULE OF RIGHT-OF-USE ASSETS Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Cost Balance, October 31, 2019 – – – – – Initial adoption of ASU 2016-02 60,418 – 23,131 – 83,549 Additions – – – 354,263 354,263 Foreign exchange effect (717 ) – (275 ) 3,686 2,694 Balance, October 31, 2020 59,701 – 22,856 357,949 440,506 Operating lease right-of-use asset, cost, beginning balance 59,701 – 22,856 357,949 440,506 Additions 91,237 287,847 – – 379,084 Foreign exchange effect 5,943 4,544 1,724 26,997 39,208 Balance, October 31, 2021 156,881 292,391 24,580 384,946 858,798 Operating lease right-of-use asset, cost, ending balance 156,881 292,391 24,580 384,946 858,798 Accumulated Depreciation Balance, October 31, 2019 – – – – – Depreciation expense 41,708 – 14,286 9,841 65,835 Foreign exchange effect 434 – 148 102 684 Balance, October 31, 2020 42,142 – 14,434 9,943 66,519 Operating lease right-of-use asset, accumulated depreciation, beginning balance 42,142 – 14,434 9,943 66,519 Depreciation expense 44,259 15,288 8,915 117,292 185,754 Foreign exchange effect 3,876 241 1,231 2,602 7,950 Balance, October 31, 2021 90,277 15,529 24,580 129,837 260,223 Operating lease right-of-use asset, accumulated depreciation, ending balance 90,277 15,529 24,580 129,837 260,223 Net Book Value Balance, October 31, 2020 17,559 – 8,422 348,006 373,987 Balance, October 31, 2021 66,604 276,862 – 255,109 598,575 Operating lease right-of-use asset 66,604 276,862 – 255,109 598,575 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

LEASE OBLIGATIONS

LEASE OBLIGATIONS	12 Months Ended
	Oct. 31, 2021
Lease Obligations
LEASE OBLIGATIONS	7. LEASE OBLIGATIONS On adoption of ASU 2016-02 on November 1, 2019, the Company recognized lease liabilities of $ 83,549 7 During the year ended October 31, 2020, the Company entered into a new operating lease with respect to its research and development pilot plant located in Burnaby, British Columbia and recognized a lease liability of $ 354,263 6 During the year ended October 31, 2021, the Company renewed its operating lease with respect to its corporate office in Vancouver, British Columbia and recognized a lease liability of $ 91,237 7 During the year ended October 31, 2021, the Company entered into a new operating lease with respect to its office in McLean,Virginia and recognized a lease liability of $ 260,649 7 SCHEDULE OF OPERATING LEASE Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Balance, October 31, 2019 – – – – – Initial adoption of ASU 2016-02 60,418 – 23,131 – 83,549 Additions – – – 354,263 354,263 Lease payments (43,627 ) – (14,990 ) (10,831 ) (69,448 ) Interest expenses 2,477 – 1,005 3,551 7,033 Foreign exchange effect (1,145 ) – 3,065 3,610 5,530 Balance, October 31, 2020 18,123 – 12,211 350,593 380,927 Additions 91,237 260,649 – – 351,886 Lease payments (47,931 ) (5,137 ) (9,457 ) (139,037 ) (201,562 ) Interest expenses 3,076 3,019 219 19,005 25,319 Prior period adjustment – – (3,065 ) – (3,065 ) Foreign exchange effect 2,099 4,081 92 24,548 30,820 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 Which consist of: Current lease obligation 46,270 16,328 – 129,447 192,045 Non-current lease obligation 20,334 246,284 – 125,662 392,280 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

MINERAL PROPERTY COSTS

MINERAL PROPERTY COSTS	12 Months Ended
	Oct. 31, 2021
Extractive Industries [Abstract]
MINERAL PROPERTY COSTS	8. MINERAL PROPERTY COSTS SCHEDULE OF MINERAL PROPERTY COSTS Beaverdell Property Silverado Property Tami Mosi Total $ $ $ $ Balance, October 31, 2019 1 1 93,452 93,454 Sale of mineral property (1 ) – – (1 ) Balance, October 31, 2020 and 2021 – 1 93,452 93,453 Sale of mineral property - – – - Balance, October 31, 2020 and 2021 – 1 93,452 93,453 [a] Beaverdell Property, Greenwood Mining Division, British Columbia, Canada The Beaverdell property is located in British Columbia, and was 100 100 50,000 37,157 37,156 1 [b] Silverado Property , The Silverado property is located in the Pinto mining district of Nevada, consists of 3 patented mining claims totaling approximately 120 hectares, and is 100 1 [c] Tami Mosi Property, Nevada, United States The Company holds a 100 1,637 2 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Oct. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	9. RELATED PARTY TRANSACTIONS [a] Deposits held by related parties During the year ended October 31, 2021, the Company provided related parties with advances that were held as deposits for anticipated future costs related to the Company’s planned magnesium research and development pilot plant and other administrative expenses (the “Pilot Plant Advances”). During the year ended October 31, 2021, the Company provided Pilot Plant Advances to a company controlled by a director and officer in the aggregate amount of $ 987,912 696,431 291,481 2,292,912 2,097,931 194,981 486,462 [b] Due to related parties As at October 31, 2021, balances due to related parties totaled $ 1,026,817 843,990 SCHEDULE OF DUE TO RELATED PARTIES October 31, 2021 October 31, 2020 $ $ Wages payable to directors and officers 357,500 161,922 Benefits payable to directors and officers 539,209 – Fees and expenses payable to directors and officers 127,878 682,068 Interests due to a shareholder 2,230 – Total 1,026,817 843,990 [c] Key management compensation As at October 31, 2021, the Company had twelve executives including eight in senior management. Their aggregate annualized compensation is approximately $ 2.9 3,020,102 1,785,032 10,248,013 300,211 [d] Transactions with related parties During the year ended October 31, 2021, the Company incurred consulting fees of CA$ 120,000 95,390 45,000 35,771 20,000 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

CONTINGENT LIABILITIES AND COMM

CONTINGENT LIABILITIES AND COMMITMENTS	12 Months Ended
	Oct. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	10. CONTINGENT LIABILITIES AND COMMITMENTS [a] Contingent liabilities [i] On September 29, 2020, James Sever filed a Notice of Civil Claim against the Company in the Supreme Court of British Columbia (the “Sever Claim”). The Sever Claim alleges that Mr. Sever had an employment and/or other similar contractual relationship with the Company, and that the Company breached such contractual relationship by way of constructive dismissal or similar conduct. The Sever Claim seeks damages in excess of $ 2.5 [ii] On December 30, 2020, the Company entered into a settlement agreement with Frank Halliday, a former director and officer of the Company, whereby the Company has agreed to pay Mr. Halliday termination pay in the amount of CA$ 102,001 76,588 [iii] On December 31, 2020, GEM Yield Bahamas Limited (“GEM”) served the Company with a Notice of Intention to Arbitrate (the “New York Arbitration Notice”) before the American Arbitration Association in New York (the “GEM New York Arbitration”). The New York Arbitration Notice alleges the Company breached a Share Subscription Agreement dated November 15, 2019 entered into between the Company and GEM (the “GEM Agreement”), among other things, claiming damages of CA$ 4.2 3.4 [iv] On February 8, 2021, GEM instituted another arbitration against the Company before the International Centre for Dispute Resolution in Montreal Canada (the “GEM Montreal Arbitration”) and joined GEM’s affiliate, GEM Global Yield LLC SCS (“GEM Global Yield” together with GEM, the “GEM Parties”). The Statement of Claim filed by the GEM Parties alleges the Company breached a Share Subscription Agreement dated November 15, 2019 and promissory note, among other things, claiming damages of approximately CA$ 4.9 3.9 33 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [v] On April 19, 2021, Lampert Advisors, LLC (“Lampert”) filed a Verified Complaint against the Company’s wholly owned subsidiary Western Magnesium Corp., a Nevada corporation (“Western Magnesium – Nevada”) in the Supreme Court of the State of New York, County of New York (the “Lampert Lawsuit”). The complaint filed in the Lampert Lawsuit alleges that Lampert entered into an agreement with Western Magnesium – Nevada to provide various financial advisory services including acquisition advisory services and act as an exclusive placement agent for a combination of debt and equity securities (the “Lampert Agreement”), that it performed all services required under that agreement and that it is owed $ 367,227 9 [b] Commitments [i] On November 1, 2016, the Company signed a contract services agreement with Lodestar Management Group, LLC (“Lodestar”), a US corporate logistics company. Lodestar provides advisory, consulting, negotiation and other management services relating to corporate management, administrative and/or operational activities of the Company. The term of the contract was for one year and has been renewed under the same terms on January 1, 2018 and 2019. The Company has agreed to compensate Lodestar in the amount of $ 1,800 2,500 0.05 1,800 2,500 21,600 nil 53,491 [ii] During the year ended October 31, 2020, the Company has entered into a lease agreement for its research and development pilot plant in Burnaby, British Columbia with a lease term from October 1, 2020 to September 30, 2023 at a monthly rent of CA$ 20,715 (USD equivalent $ 16,727 ). In June 2021, the Company renewed its sublease agreement with a company controlled by a director and officer for its corporate office in Vancouver, British Columbia with a lease term from April 1, 2021 to March 31, 2023 at a monthly rent of CA$ 9,794 (USD equivalent $ 7,909 ). In September 2021, the Company entered into a lease agreement for its office in McLean, Virginia with a lease term from September 14, 2021 to February 28, 2025 at a monthly rent of $ 9,113 . The Company will be abated for the beginning five months and is entitled to a tenant allowance of $ 41,010 [notes 6 and 7] [iii] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5 5 9,163,425 0.65 5,956,226 4,796,832

PROMISSORY NOTE

PROMISSORY NOTE	12 Months Ended
	Oct. 31, 2021
Promissory Note
PROMISSORY NOTE	11. PROMISSORY NOTE During the year ended October 31, 2019, the Company received a loan of CA$ 150,000 112,895 18 60,000 44,588 210,000 157,483 1,639 16,655 65,761 101,066 nil 60,567

PROVISION FOR FLOW THROUGH SHAR

PROVISION FOR FLOW THROUGH SHARE ISSUANCES	12 Months Ended
	Oct. 31, 2021
Provision For Flow Through Share Issuances
PROVISION FOR FLOW THROUGH SHARE ISSUANCES	12. PROVISION FOR FLOW THROUGH SHARE ISSUANCES The Company has recorded a provision in the amount of $ 233,285 216,924 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

CONVERTIBLE DEBENTURE

CONVERTIBLE DEBENTURE	12 Months Ended
	Oct. 31, 2021
Debt Disclosure [Abstract]
CONVERTIBLE DEBENTURE	13. CONVERTIBLE DEBENTURE [a] July 2020 Convertible Debenture On July 27, 2020, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of CA$ 150,000 (USD equivalent $ 112,124 , the “July 2020 Convertible Debenture”). The note bears interest at 12 % per annum and is due on the date that is one year following the closing date. The note is convertible into common shares of the Company at the price which is the greater of CA$ 0.15 per common share and the market price on the date of the conversion notice. Any accrued but unpaid interest will be payable on the earlier of the maturity date and the date of conversion in cash or common shares. No finder’s fees were paid in connection with this private placement. On May 18, 2021, the Company issued a total of 1,360,959 common shares on the conversion of the July 2020 Convertible Debenture including conversion of accrued interest and 263,973 common shares valued at $ 26,286 in transaction costs. [b] July 2021 Convertible Debenture On July 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of CA$ 100,000 79,542 12 0.12 0.20 7,299 5,802 effective interest rate of 1,878% 100,000 79,542 [c] June 2021 Convertible Debenture On June 15, 2021, the Company closed a non-brokered private placement of an unsecured convertible note in the principal amount of $ 1,500,000 12 December 10, 2022 15,000,000 one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion. As part of the offering of the June 2021 Convertible Debenture, the Company also entered into the June 10, 2021 Securities Purchase Agreement (the “Securities Purchase Agreement”), whereby the Company agreed to use commercially reasonable efforts to file a registration statement with the United States Securities and Exchange Commission (the “SEC”) by August 14, 2021, covering the public resale of the shares of common stock underlying such debenture and, upon its conversion, the Class A and B Warrants issuable upon such conversion (the “Underlying Shares”), and to use its best efforts to cause the registration statement to be declared effective on October 13, 2021 [note 19[vi]] In addition to certain covenants contained in the Securities Purchase Agreement, the terms of the June 2021 Convertible Debenture contain certain negative covenants by the Company, including, among others, sell or offer to sell any securities with non-fixed or floating price features, issue any common stock or common stock equivalents at a price lower than the Conversion Price herein then in effect, or issue any equity or debt instruments with anti-dilution provisions. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated In the event the Company issues or sells any common stock or common stock equivalents with terms that the purchaser holding the outstanding June 2021 Convertible Debenture (the “Convertible Debenture Holder”) or the Class A and B Warrants reasonably believes are more favorable to such holder than the terms of the June 2021 Convertible Debenture or the Class A and B Warrants, then upon notice to the Company by such holder within five trading days after notice to such holder by the Company, the Company will use commercially reasonable efforts to obtain the approval of the TSX-V and any additional required regulatory approval to amend the terms of the June 2021 Convertible Debenture or the Class A and B Warrants as required, as the case may be, so as to give such holder the benefit of such more favorable terms or conditions. The conversion price of the June 2021 Convertible Debenture and the exercise price of the Class A and B Warrants are subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events, including merger or consolidation of the Company or in a “Fundamental Transaction” as defined in the June 2021 Convertible Debenture. The Company has granted the holders certain rights of first refusal on its future offerings for as long as the June 2021 Convertible Debenture or the Class A and B Warrants are outstanding. The Company may prepay and satisfy the June 2021 Convertible Debenture so long as an event of default has not occurred, upon 20 days’ prior written notice received by the Company to the holder, by paying 125% of the amounts owed on the June 2021 Convertible Debenture, including all principal, interest and other fees. The holder of this debenture may, however, convert all or a portion of the debenture during the 20-day notice period. As at October 31, 2021, the Company incurred contractual interest of $ 70,521 Subsequent to October 31, 2021, the Company issued an aggregate 3,000,000 3,000,000 1,500,000 0.13 1,500,000 0.19 [note 19[iii]] [d] Debt Host Liability and Embedded Derivative Liability The July 2020 Convertible Debenture and the June 2021 Convertible Debenture were determined to be hybrid financial instruments comprised of a debt host liability and an embedded derivative liability, as under the conversion feature the number of shares that will or may be issued to settle the notes may vary. The Company uses the Black-Scholes Option Pricing Model based on different default risks and assumptions. The debt host liability of the convertible note will be measured at amortized cost, with the embedded derivative liability measured at fair value through profit and loss. On issuance date of the July 2020 Convertible Debenture, the fair value of its debt host liability was determined to be $ 87,083 25,041 nil 96,318 nil 20,123 nil 116,441 37 On issuance date of the June 2021 Convertible Debenture, the embedded derivative liability was valued at $ 1,646,600 1,500,000 1 146,601 44 nil 7,449,700 nil 7,449,744 nil 1,448 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated The inputs used in the Black-Scholes Option Pricing Model are as follows: SCHEDULE OF OPTION PRICING MODEL October 31, June 15, July 27, 2021 2021 2020 Risk free rate of interest 1.08 % 0.31 % 0.26 % Expected life in years 1.11 1.50 0.74 Conversion exercise price $ 0.10 $ 0.10 CA$ 0.15 Underlying share price of the Company CA$ 0.73 CA$ 0.23 CA$ 0.13 Expected volatility 107.62 % 87.17 % 82.54 % Expected dividend rate Nil Nil Nil SCHEDULE OF DERIVATIVE INSTRUMENTS July 2020 Convertible Debenture June 2021 Convertible Debenture July 2021 Convertible Debenture Total $ $ $ $ Debt Host Liability Balance, October 31, 2019 – – – – Value of debt host liability recognized 87,083 – – 87,083 Accretion and interest expense 8,751 – – 8,751 Foreign currency translation 484 – – 484 Balance, October 31, 2020 96,318 – – 96,318 Value of debt host liability recognized – 1 – 1 Accretion and interest expense 23,587 43 63 23,693 Conversion (125,560 ) – – (125,560 ) Foreign currency translation 5,655 – – 5,655 Balance, October 31, 2021 – 44 63 107 Embedded Derivative Liability Balance, October 31, 2019 – – – – Fair value of embedded derivative liability recognized 25,041 – – 25,041 Fair value adjustment (4,979 ) – – (4,979 ) Foreign currency translation 61 – – 61 Balance, October 31, 2020 20,123 – – 20,123 Fair value of embedded derivative liability recognized – 1,646,600 – 1,646,600 Fair value adjustment (16,058 ) 5,717,328 – 5,701,270 Conversion (5,247 ) – – (5,247 ) Foreign currency translation 1,182 85,772 – 86,954 Balance, October 31, 2021 – 7,449,700 – 7,449,700 Combined Value of Convertible Debenture Balance, October 31, 2019 – – – – Conversion – – – – Balance, October 31, 2020 116,441 – – 116,441 Conversion – – – – Balance, October 31, 2021 – 7,449,744 63 7,449,807 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

SHARE CAPITAL

SHARE CAPITAL	12 Months Ended
	Oct. 31, 2021
Equity [Abstract]
SHARE CAPITAL	14. SHARE CAPITAL [a] Authorized capital The authorized share capital consists of 1,000,000,000 0.001 [b] Common shares issued Fiscal 2020 [i] On December 20, 2019, the Company exercised its right to call, subject to acceleration provisions, all outstanding common share purchase warrants set to expire between May 7, 2020 and May 13, 2021. The expiry was amended to January 19, 2020. This expiry date was then extended to February 19, 2020 35,472,661 0.08 24,794,484 4,864,000 0.05 [ii] On January 17, 2020, the Company closed a non-brokered private placement consisting of 3,643,792 0.15 546,569 416,719 52,922 39,722 Each unit consists of one common share and one common share purchase warrant exercisable at a price of CA$0.21 per common share for a period of one year. The expiration date of these common share purchase warrants was subsequently extended to August 31, 2021. These common share purchase warrants were subject to an expiry acceleration provision, upon thirty days’ written notice, should the price of the Company’s common shares exceed CA$0.30 for at least ten consecutive trading days. 41,275 [iii] On May 26, 2020, the Company issued a total of 500,000 37,000 26,401 19,775 [iv] On September 10, 2020, the Company announced a non-brokered private placement of up to 53,846,154 0.13 7,000,000 Each unit is comprised of one common share and one common share purchase warrant exercisable at CA$0.19 per common share for a period of one year. 747,392 596,872 [note 14[f]] Fiscal 2021 [i] In connection with the non-brokered private placement announced on September 10, 2020: On November 20, 2020, the Company closed the first tranche of the non-brokered private placement, issuing 5,599,171 0.13 727,892 556,876 On January 15, 2021, the Company closed the second tranche of the non-brokered private placement, consisting of 7,337,914 0.13 953,930 749,435 39,996 On January 29, 2021, the Company closed the third tranche of the non-brokered private placement consisting of 5,382,303 0.13 699,699 547,496 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated On March 24, 2021, the Company closed the fourth tranche of the non-brokered private placement consisting of 6,554,172 0.13 852,042 678,270 On April 27, 2021, the Company closed the fifth and final tranche of the non-brokered private placement consisting of 851,395 0.13 110,681 89,237 In total, the Company issued an aggregate 25,724,955 0.13 3,344,244 2,621,314 Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche. 195,614 [ii] On May 5, 2021, the Company announced a non-brokered private placement priced at CA$ 0.13 3,000,000 5,223,420 0.13 679,044 561,844 17,853,506 0.13 2,320,956 1,880,687 23,076,926 0.13 3,000,000 2,442,531 Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche. 154,336 [iii] On May 18, 2021, the Company issued a total of 1,360,959 263,973 26,286 [iv] On June 7, 2021, the Company issued 1,538,461 0.24 369,231 305,832 [v] On July 16, 2021, the Company closed a non-brokered private placement and issued 4,350,000 0.20 870,000 690,860 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing. 48,319 [vi] On August 11, 2021, the Company closed a non-brokered private placement and issued 3,827,601 0.55 0.44 2,105,180 1,683,336 Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 (US$0.52) for a period of eighteen months from the date of closing. 116,479 [vii] During the year ended October 31, 2021, the Company issued a total of 7,014,969 0.05 0.21 1,120,130 887,520 525,173 [viii] During the year ended October 31, 2021, the Company issued a total of 2,630,000 0.05 0.16 175,800 140,734 [ix] With respect to the exercises of common share purchase warrants and options, the Company reclassified $ 4,291 121,932 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [x] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5 5 9,163,425 0.65 5,956,226 4,796,832 [c] Common share purchase warrants A summary of the changes in the Company’s common share purchase warrants during the year ended October 31, 2021 are as follows: SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS Expiry Date Exercise Price (CA$) Weighted Average Life (Years) October 31, Granted Exercised Expired/ Cancelled October 31, 2021 August 31, 2021* 0.21 – 3,643,791 - (3,118,618 ) (525,173 ) – November 22, 2021 0.19 0.14 – 5,599,171 (1,439,150 ) – 4,160,021 January 17, 2022 0.19 0.29 – 7,337,914 (70,000 ) – 7,267,914 January 31, 2022 0.19 0.33 – 5,382,303 – – 5,382,303 February 21, 2022 0.05 0.39 1,505,200 – – – 1,505,200 March 24, 2022 0.19 0.48 – 6,554,172 (212,300 ) – 6,341,872 March 27, 2022 0.05 0.49 1,482,025 – (500,000 ) – 982,025 April 27, 2022 0.19 0.57 – 851,395 (60,000 ) – 791,395 May 9, 2022 0.05 0.61 2,368,626 – (554,901 ) – 1,813,725 May 30, 2022 0.19 0.66 – 5,223,420 – – 5,223,420 June 17, 2022 0.19 0.71 – 17,853,506 (150,000 ) – 17,703,506 July 18, 2022 0.30 0.79 – 4,350,000 – – 4,350,000 August 14, 2022 0.05 0.87 1,110,000 – (910,000 ) – 200,000 February 13, 2023 0.65 1.37 – 3,827,601 – – 3,827,601 Total 10,109,642 56,979,482 (7,014,969 ) (525,173 ) 59,548,982 Weighted average exercise price CA$ 0.11 CA$ 0.23 CA$ 0.16 CA$ 0.21 CA$ 0.22 * The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 warrants, extending the expiry date from January 17, 2021 to August 31, 2021, subject to acceleration if the closing price of the Company’s shares exceeds CA$ 0.30 per common share for at least 10 consecutive trading days. A summary of the changes in the Company’s common share purchase warrants during the year ended October 31, 2020 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2019 Granted Exercised Expired/ Cancelled October 31, 2020 January 17, 2021 0.21 – – 3,643,791 – – 3,643,791 February 21, 2022 0.05 2.31 1,505,200 – – – 1,505,200 March 27, 2022 0.05 2.41 3,426,025 – (1,944,000 ) – 1,482,025 May 9, 2022 0.05 2.52 5,088,626 – (2,720,000 ) – 2,368,626 August 14, 2022 0.05 2.79 1,310,000 – (200,000 ) – 1,110,000 May 7, 2020* 0.07 – 3,100,000 – (3,000,000 ) (100,000 ) – October 4, 2020* 0.08 – 5,016,000 – (3,425,000 ) (1,591,000 ) – November 30, 2020* 0.08 – 6,169,926 – (3,091,383 ) (3,078,543 ) – January 23, 2021* 0.08 – 6,388,435 – (3,409,160 ) (2,979,275 ) – March 29, 2021* 0.08 – 8,188,046 – (4,496,710 ) (3,691,336 ) – May 13, 2021* 0.08 – 31,404,738 – (18,050,408 ) (13,354,330 ) – Total 71,596,996 3,643,791 (40,336,661 ) (24,794,484 ) 10,109,642 Weighted average exercise price CA$ 0.07 CA$ 0.21 CA$ 0.08 CA$ 0.08 CA$ 0.11 * On December 20, 2019, the Company exercised its right to call, subject to acceleration provisions, all outstanding warrants set to expire between May 7, 2020 and May 13, 2021. The expiry was amended to January 19, 2020. This expiry date was then extended to February 19, 2020. Any unexercised warrants were voided and of no value after February 19, 2020. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated [d] Stock options The Company has adopted an incentive stock option plan, effective on August 8, 2017 and as amended on August 8, 2018, under the rules of the TSX-V pursuant to which it is authorized to grant stock options to executive officers, directors, employees and consultants, enabling them to acquire up to 20% Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company. On June 11, 2021, the Company adopted the 2021 Equity Incentive Plan which replaces the 2017 Stock Option for providing stock-based compensation to directors, officers, employees, consultants, and advisors of the Company and no further options will be granted under the 2017 Stock Option Plan. Under the 2021 Equity Incentive Plan, the Company is authorized to issue up 27,312,368 1,730,000 During the year ended October 31, 2020, the Company granted 6,600,000 0.11 0.16 two five years On December 30, 2020, the Company granted 15,650,000 0.13 9,500,000 6,150,000 On August 30, 2021, the Company granted 21,700,000 0.70 five years On October 1, 2021, the Company granted 1,450,000 0.50 five years WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated As at October 31, 2021, the maximum number of common shares available under the 2021 Equity Incentive Plan was 29,042,368 5,892,368 During the year ended October 31, 2021, the Company recognized a net stock-based compensation totaling $ 11,051,124 666,259 The weighted average grant date fair value of the stock options granted during the year ended October 31, 2021 was CA$ 0.36 0.14 SCHEDULE OF ASSUMPTIONS USED 2021 2020 Risk free rate of interest 0.20 1.07 % 0.43 1.51 % Expected life of options 2 5 5 Exercise price of options CA$ 0.13 0.70 CA$ 0.11 0.16 Expected annualized volatility 130.88 140.05 % 120.13 188.46 % Expected dividend rate Nil Nil A summary of the changes in the Company’s stock options during the year ended October 31, 2021 are as follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2020 Granted Exercised Expired/ Cancelled Outstanding as at October 31, 2021 Vested as at October 31, 2021 February 11, 2021 0.05 – 800,000 – – (800,000 ) – – August 16, 2021 0.05 – 600,000 – (600,000 ) – – – March 27, 2022 0.05 0.40 1,750,000 – (250,000 ) – 1,500,000 1,500,000 August 26, 2022 0.13 – 500,000 – – (500,000 ) – – December 30, 2022 0.13 1.16 – 6,150,000 (100,000 ) (50,000 ) 6,000,000 5,837,500 April 19, 2023 0.05 – 800,000 – – (800,000 ) – – August 12, 2023 0.05 1.78 3,120,000 – (600,000 ) (230,000 ) 2,290,000 2,290,000 December 3, 2023 0.05 2.09 7,000,000 – (550,000 ) – 6,450,000 6,450,000 May 22, 2024 0.12 2.56 7,950,000 – – (50,000 ) 7,900,000 7,900,000 November 3, 2024 0.15 3.01 700,000 – – – 700,000 700,000 November 24, 2024 0.16 3.07 900,000 – (30,000 ) (550,000 ) 320,000 320,000 March 26, 2025 0.11 3.40 300,000 – (200,000 ) – 100,000 100,000 April 23, 2025 0.12 3.48 4,000,000 – (300,000 ) (350,000 ) 3,350,000 3,350,000 December 30, 2025 0.13 4.17 – 9,500,000 – – 9,500,000 9,500,000 August 30, 2026 0.70 4.83 – 21,700,000 – – 21,700,000 21,400,000 October 1, 2026 0.50 4.92 – 1,450,000 – – 1,450,000 1,450,000 Total 28,420,000 38,800,000 (2,630,000 ) (3,330,000 ) 61,260,000 60,797,500 Weighted average exercise price CA$0.09 CA$0.46 CA$0.07 CA$0.09 CA$0.33 CA$0.32 Aggregate intrinsic value $ 19,994,025 $ 19,908,026 Weighted average remaining life 3.46 3.46 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated A summary of the changes in the Company’s nonvested stock options during the year ended October 31, 2021 are as follows: SCHEDULE OF NONVESTED STOCK OPTIONS Expiry Date Fair Value Per Share Weighted Average Life (Years) Nonvested as at October 31, 2020 Granted Vested Expired/ Cancelled Nonvested as at October 31, 2021 December 30, 2022 0.07 1.16 – 650,000 487,500 – 162,500 August 30, 2026 0.56 4.83 – 300,000 – – 300,000 Total – 950,000 487,500 – 462,500 Weighted average grant date fair value – per option – CA$0.22 CA$0.07 – CA$0.39 Weighted average grant date fair value – total – $ 170,781 $ 26,650 – $ 144,131 A summary of the changes in the Company’s stock options during the year ended October 31, 2020 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2019 Granted Exercised Expired/ Cancelled Outstanding as at October 31, 2020 Vested as at October 31, 2020 May 31, 2020 0.08 – 400,000 – (400,000 ) – – – June 3, 2020 0.05 – 550,000 – – (550,000 ) – – February 11, 2021 0.05 0.53 1,300,000 – – (500,000 ) 800,000 800,000 August 16, 2021 0.05 1.04 1,200,000 – – (600,000 ) 600,000 600,000 March 27, 2022 0.05 1.65 2,000,000 – – (250,000 ) 1,750,000 1,750,000 August 26, 2022 0.13 – – 500,000 – – 500,000 – April 19, 2023 0.05 2.72 800,000 – – – 800,000 800,000 August 12, 2023 0.05 3.03 3,780,000 – (100,000 ) (560,000 ) 3,120,000 3,120,000 December 3, 2023 0.05 3.35 9,600,000 – – (2,600,000 ) 7,000,000 7,000,000 May 22, 2024 0.12 3.81 10,000,000 – – (2,050,000 ) 7,950,000 7,950,000 November 3, 2024 0.15 4.27 – 700,000 – – 700,000 700,000 November 24, 2024 0.16 4.32 – 900,000 – – 900,000 775,000 March 26, 2025 0.11 4.66 – 300,000 – – 300,000 300,000 April 23, 2025 0.12 4.73 – 4,200,000 – (200,000 ) 4,000,000 3,625,000 Total 29,630,000 6,600,000 (500,000 ) (7,310,000 ) 28,420,000 27,420,000 Weighted average exercise price CA$0.07 CA$0.13 CA$0.07 CA$0.07 CA$0.09 CA$0.09 Aggregate intrinsic value $ 801,922 $ 866,441 Weighted average remaining life 3.18 3.18 The intrinsic value of options exercised during the year ended October 31, 2021 was $ 962,936 28,533 [e] Share-based payments and other reserves The share-based payments and other reserves are used to recognize the fair value of stock options granted to executive officers, directors, employees and consultants as part of their remuneration, as well as those of broker warrants issued in relation to the Company’s financings. When stock options and broker warrants are subsequently exercised, the fair value of such stock options and broker warrants in reserves is credited to share capital. Common share purchase warrants attached to units as part of a unit placement are assigned a $nil value. The residual method is used to calculate the fair value of the warrant component of units issued, whereby the residual of the private placement proceeds less the fair value of the share component is assigned as the fair value of the warrants. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated In addition, the Company has allocated the intrinsic value of the beneficial conversion feature of the July 2021 Convertible Debenture capped at the face value of CA$ 100,000 79,542 [f] Obligations to issue shares As at October 31, 2021, the Company received advance share subscriptions in the amount of $ 209,827 596,872 [note 19[iv]] [g] Dilutive common shares For the year ended October 31, 2021, potentially dilutive common shares relating to common share purchase warrants and options outstanding totaling 120,808,982 38,529,642

CAPITAL MANAGEMENT

CAPITAL MANAGEMENT	12 Months Ended
	Oct. 31, 2021
Capital Management
CAPITAL MANAGEMENT	15. CAPITAL MANAGEMENT The Company classifies the components of shareholders’ equity as capital, which at October 31, 2021, was a deficiency of $ 6,770,038 2,079,903 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

FINANCIAL INSTRUMENTS AND FINAN

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT	12 Months Ended
	Oct. 31, 2021
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT	16. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT The Company’s classification of its financial instruments is as follows: SCHEDULE OF CLASSIFICATION OF ITS FINANCIAL INSTRUMENTS Financial Instruments Measurement Method Associated Risk Fair Value at October 31, 2021 ($) Cash FVTPL Credit and currency 462,360 Amounts receivable Amortized cost Credit and currency 151,485 Deposits held by related parties Amortized cost Credit and currency 486,462 Accounts payable and accrued liabilities Amortized cost Currency 1,989,316 Due to related parties Amortized cost Currency 1,026,817 Convertible debenture Amortized cost Currency 107 Convertible debenture - derivative liability FVTPL Currency 7,449,700 [a] Fair value The fair value of financial instruments is the amount of consideration that would be agreed upon in an arm’s length transaction between knowledgeable, willing parties who are under no compulsion to act. The fair value of current financial instruments except derivative liability approximates their carrying values as long as they are short-term in nature or bear interest at market rates. [b] Fair value hierarchy Financial instruments that are held at fair value are categorized based on a valuation hierarchy which is determined by the valuation methodology utilized. The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1 Level 2 Level 3 Cash and cash equivalents are valued using a market approach based upon unadjusted quoted prices for identical assets in an active market obtained from securities exchanges. As at October 31, 2021, the fair value of cash and cash equivalents held by the Company was based on Level 1 of the fair value hierarchy. There were no transfers between Levels 1 and 2 during the period. The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. The inputs used in determining the fair value of the embedded derivative are disclosed in note 13[d] [c] Financial risk management The Company’s board of directors has the overall responsibility for the establishment and oversight of the Company’s risk management framework. The Company’s risk management policies are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and in response to the Company’s activities. Management regularly monitors compliance with the Company’s risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. In the normal course of operations, the Company is exposed to various risks such interest rate, foreign exchange, commodity, credit, and liquidity. To manage these risks, management determines what activities must be undertaken to minimize potential exposure to risks. The objectives of the Company in managing risks are as follows: ● Maintaining sound financial condition: ● Financing operations; and ● Ensuring liquidity to all operations. In order to satisfy these objectives, the Company has adopted the following policies: ● Prepare budget documents at prevailing market rates to ensure clear corporate alignment to performance management and achievement of targets; ● Recognize and observe the extent of operating risk within the business; and ● Identify the magnitude of the impact of market risk factors on the overall risk of the business and take advantage of natural risk reductions that arise from these relationships. [i] Interest rate risk Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in the market interest rates. The Company is exposed to interest rate risk on its cash on deposits with banks and, from time to time, on its holdings of short-term investments. As of October 31, 2021, the Company had $ 462,360 39,571 no [ii] Foreign currency risk The Company is exposed to foreign currency risk on fluctuations related to cash, deposits held by related parties, accounts payable, due to related parties and convertible debenture that are denominated in US dollars. The Company has not entered into foreign exchange derivative contracts. A significant change in the currency exchange rates between the Canadian dollar relative to the US dollar could have a material effect on the Company’s financial position, results of operations, or cash flows. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated Based on the Company net exposures as at October 31, 2021, assuming that all other variables remain constant, a 5% 262,941 SCHEDULE OF FOREIGN CURRENCY RISK October 31, 2021 $ Cash 186,627 Deposits held by related parties 486,462 Accounts payable and accrued liabilities (773,011 ) Due to related parties (467,500 ) Convertible debenture (1,500,000 ) Total (2,067,422 ) [iii] Commodity price risk The value of the Company’s magnesium production business and its exploration and evaluation assets are dependent on the price of magnesium and the outlook for this mineral. Market prices for these metals historically have fluctuated widely and are affected by numerous factors outside the Company’s control, including but not limited to, levels of worldwide production, short-term changes in supply and demand, industrial and retail demand, as well as certain other factors related specifically to magnesium. If magnesium prices decline for a prolonged period below the cost of production, it may not be economically feasible to continue towards production. [iv] Credit risk Credit risk is the risk of loss if counterparties do not fulfill their contractual obligations and arises principally from trade receivables. The Company’s credit risk is primarily attributable to cash, and deposits held by related parties. The Company limits its exposure to credit risk on cash as these financial instruments are held with major Canadian and international banks. Amounts receivable consist primarily of GST due from the Federal Government of Canada. Management believes the credit risk concentration with respect to amounts receivable is remote. The carrying amount of financial assets recorded in the financial statements, net of any allowances, represents the Company’s maximum exposure to credit risk. [v] Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they come due. The Company’s exposure to liquidity risk is dependent on its purchasing commitments and obligations and its ability to raise funds to meet commitments and sustain operations. The Company manages liquidity risk by continuously monitoring its actual and forecasted working capital requirements to ensure there is capital to meet short-term and long-term obligations. As of October 31, 2021 and October 31, 2020, the Company had working capital deficiency of $ 9,657,316 2,392,189 note 1 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

SEGMENTED INFORMATION

SEGMENTED INFORMATION	12 Months Ended
	Oct. 31, 2021
Segment Reporting [Abstract]
SEGMENTED INFORMATION	17. SEGMENTED INFORMATION The Company focuses on plant operations and magnesium production and continues to move towards the buildout of its pilot plant facility and the development of a full-scale commercial magnesium production facility. The Company also owns mining claims for the exploration and development of mineral property interests. Geographic information for the Company’s assets is as follows: SCHEDULE OF ASSETS INFORMATION October 31, 2021 October 31, 2020 $ $ Canada – property, plant and equipment 2,546,383 79,436 United States – property, plant and equipment 28,321 – United States – mineral property costs 93,453 93,453 Asset 2,668,157 172,889 Canada – other assets 1,554,827 533,815 United States – other assets 290,528 2,059 1,845,355 535,874 Total Assets 4,513,512 708,763

INCOME TAX

INCOME TAX	12 Months Ended
	Oct. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAX	18. INCOME TAX Significant items resulting in the difference between the Company’s income tax rate and the federal statutory rate are as follows: SCHEDULE OF EFFECTIVE TAX RATES RECONCILIATION 2021 2020 $ $ Loss for the year (23,549,612 ) (4,672,605 ) Effective statutory rate 33.02 % 31.21 % Expected income tax recovery at statutory rate (7,778,880 ) (1,458,320 ) Net adjustment for deductible and non-deductible amounts 2,636,262 250,196 Foreign exchange effect (9,867 ) (175,597 ) Valuation allowance 5,152,485 1,383,721 Deferred income tax provision (recovery) – – The Company’s deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITY 2021 2020 $ $ Non-capital loss carry-forwards 5,340,578 2,600,561 Property and equipment (159,673 ) (123,561 ) Lease liability 180,812 103,789 Convertible debenture (509,985 ) – Convertible debenture – derivative liability 2,532,898 – Exploration and evaluation asset 359,700 - Share issue costs - 11,056 Valuation allowance (7,744,330 ) (2,591,845 ) Deferred income tax asset (liability) – – The Company has approximately $ 13,439,000 3,515,000 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Oct. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	19. SUBSEQUENT EVENTS [i] Subsequent to October 31, 2021, upon exercise of common share purchase warrants, the Company issued an aggregate 15,159,448 0.19 2,880,295 200,000 0.05 10,000 30,000 0.30 9,000 2,428,363 [ii] Pursuant to an agreement entered on August 29, 2018 and which was approved by the TSX-V on September 12, 2018, a company controlled by a director and officer is eligible to receive up to 5% 5 9,163,425 0.65 5,956,226 4,796,832 [iii] On November 4, 2021, the Company issued 1,000,000 1,000,000 500,000 0.13 500,000 0.19 1,000,000 1,000,000 500,000 0.13 500,000 0.19 1,000,000 1,000,000 500,000 0.13 500,000 0.19 [iv] On November 26, 2021, the Company closed a non-brokered private placement and issued 1,375,499 0.55 756,524 0.75 [v] On December 3, 2021, the Company granted 250,000 0.58 five years [vi] On December 13, 2021, the Company’s Form 10 Registration Statement filed with the US SEC was declared effective, and the Company will be subject to the reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”).

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Oct. 31, 2021
Accounting Policies [Abstract]
Principles of consolidation	[a] Principles of consolidation These Financial Statements include the accounts of the Company and its wholly owned and controlled subsidiaries as described in note 2
Foreign currency	[b] Foreign currency Items included in the financial statements of each consolidated entity are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). Foreign currency transactions are translated into the functional currency using the prevailing exchange rates on the dates of transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency of an entity are recognized in the statements of loss and comprehensive loss. Assets and liabilities of the Company and its subsidiary with a functional currency in Canadian dollars are translated at the period end rates of exchange, and the results of its operations are translated at average rates of exchange for the period. Equity transactions have been translated using historical rates in effect on the date that each transaction occurred. The resulting translation adjustments are included in accumulated other comprehensive income or loss as shareholders’ equity or deficit. Additionally, foreign exchange gains and losses related to certain intercompany loans that are permanent in nature are included in accumulated other comprehensive income or loss.
Cash and cash equivalents	[c] Cash and cash equivalents Cash and cash equivalents include highly liquid financial instruments that are readily convertible into cash with original maturities of three months or less.
Property, plant and equipment	[d] Property, plant and equipment Property, plant and equipment (“PP&E”) is carried at cost, less accumulated depreciation and accumulated impairment losses. The cost of an item of PP&E consists of the purchase price, any costs directly attributable to bringing the asset to the location and condition necessary for its intended use and an initial estimate of the costs of dismantling and removing the item and restoring the site on which it is located. Depreciation is provided at rates calculated to write off the cost of PP&E, less their estimated residual value. The depreciation rates and method applicable to each category of property, plant and equipment are as follows: SCHEDULE OF DEPRECIATION RATE Class Rate Computer equipment 55% declining balance Furniture 20% declining balance Plant equipment 20% declining balance Furnace To be determined Leasehold improvement Term of lease Right-of-use assets Term of lease WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated An item of PP&E is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on disposal of the asset, determined as the difference between the net disposal proceeds and the carrying amount of the asset, is recognized in profit or loss in the consolidated statements of loss and comprehensive loss. Where an item of PP&E comprises major components with different useful lives, the components are accounted for as separate items. Expenditures incurred to replace a component of an item of PP&E that is accounted for separately, including major inspection and overhaul expenditures, are capitalized.
Reclamation deposits	[e] Reclamation deposits The Company maintains cash deposits, as required by regulatory bodies, as assurance for the funding of decommissioning costs. These funds are restricted to that purpose and are not available to the Company until the reclamation obligations have been fulfilled and are therefore classified as long-term assets.
Research and development	[f] Research and development Expenditures on research activities taken to develop a pyro metallurgical process to extract and recover magnesium metal from dolomite are expensed as incurred. Development expenditures are expensed in the period incurred.
Mineral property acquisition and exploration assets	[g] Mineral property acquisition and exploration assets Mineral property acquisition costs are capitalized when incurred. Acquisition costs include cash consideration and the fair market value of shares issued on the acquisition of mineral property claims. Costs related to the development of mineral reserves are capitalized when it has been determined an ore body can be economically developed. The development stage begins when an ore body is determined to be economically recoverable based on proven and probable reserves and appropriate permits are in place, and ends when the production stage or exploitation of reserves begins. Major mine development expenditures are capitalized, including primary development costs such as costs of building access ways, tailings impoundment, development of water supply and infrastructure developments. Exploration costs include those relating to activities carried out (a) in search of previously unidentified mineral deposits, or (b) at undeveloped concessions. Pre-development activities involve costs incurred in the exploration stage that may ultimately benefit production that are expensed due to the lack of evidence of economic development, which is necessary to demonstrate future recoverability of these expenses. Secondary development costs are incurred for preparation of an ore body for production in a specific ore block or work area, providing a relatively short-lived benefit only to the mine area they relate to, and not to the ore body as a whole. All exploration costs have been expensed. Once production has commenced, capitalized costs will be depleted using the units-of-production method over the estimated life of the proven and probable reserves. If mineral properties are subsequently abandoned or impaired, any capitalized costs will be charged to the consolidated statements of loss and comprehensive loss in that period. The carrying cost of mineral properties is assessed for impairment whenever information or circumstances indicate the potential for impairment. Such evaluations compare estimated future net cash flows with carrying costs and future obligations on an undiscounted basis. If it is determined that the future undiscounted cash flows are less than the carrying value of the property, a write down to the estimated fair value is charged to the consolidated statements of loss and comprehensive loss for the period. Where estimates of future net cash flows are not available and where other conditions suggest impairment, management assesses if the carrying value can be recovered. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated Management conducted an impairment test on its mineral properties for recoverability and impairment loss during the years ended October 31, 2021 and 2020 and determined that its mineral properties were not impaired. For significant development projects, interest is capitalized as part of the historical cost of developing and constructing assets in accordance with ASC 835-20. Interest is capitalized until the asset is ready for service. Capitalized interest is determined by multiplying the Company’s weighted-average borrowing cost on general debt by the average amount of qualifying costs incurred. Once an asset subject to interest capitalization is completed and placed in service, the associated capitalized interest is expensed through depletion or impairment.
Impairment of non-financial assets	[h] Impairment of non-financial assets Non-financial assets are evaluated at the end of each reporting period by management for indicators that carrying value is impaired and may not be recoverable. When indicators of impairment are present, non-financial assets are tested for impairment as an individual asset, as part of an asset group or at the reporting unit (“RU”) level. An asset group is the lowest level for which there are identifiable cash flows (i.e. both cash inflows and cash outflows) that are largely independent of the net cash flows of other groups of assets. An RU is an operating segment or one level below an operating segment if certain conditions are met. Impairment tests for non-financial assets subject to depreciation or amortization are applied to individual assets if possible. If this is not possible, then these assets are tested for impairment at the asset group level. An impairment loss is triggered for non-financial assets only if the asset’s, or asset group’s, carrying amount exceeds its recoverable amount (i.e. the carrying amount is greater than the undiscounted cash flows of the asset or asset group). If the carrying amount is not recoverable, then the impairment loss is the difference between the carrying amount of the asset (asset group) and the fair value of the asset (asset group). An impairment loss for an asset group is allocated pro rata to the non-financial assets in the asset group. Impairment losses are recognized in the consolidated statements of loss and comprehensive loss and are not reversed.
Income taxes	[i] Income taxes The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company has adopted the provisions of FASB ASC 740 “Income Taxes” regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of loss and comprehensive loss. When applicable, the Company classifies penalties and interest associated with uncertain tax positions as a component of income tax expense in its consolidated statements of loss and comprehensive loss. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated
Loss per share	[j] Loss per share Basic earnings (loss) per share (“EPS”) is calculated by dividing profit or loss attributable to ordinary equity holders (numerator) by the weighted average number of ordinary shares outstanding (denominator) during the period. The denominator is calculated by adjusting the shares issued at the beginning of the period by the number of shares bought back during the period, multiplied by a time-weighting factor. Diluted EPS is calculated by adjusting the earnings and number of shares for the effects of dilutive options and other dilutive potential units. The effects of anti-dilutive options and potential units are ignored in calculating diluted EPS. All options and potential units are considered anti-dilutive when the Company is in a loss position.
Share-based payments	[k] Share-based payments The Company has an equity-settled share purchase stock option plan that is described in note 14 The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity-based instruments. The cost of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. The Company accounts for the granting of stock options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all stock options is expensed over their vesting period with a corresponding increase to additional paid-in capital. Compensation costs for stock-based payments that do not include performance conditions are recognized on a straight-line basis. Compensation cost associated with a share-based award having a performance condition is only recognized over the requisite service period if it is probable. Share-based awards with a performance condition are accrued on an award by award basis. The share-based compensation fair value is determined using an estimated forfeiture rate. Compensation ultimately recognized is revised in subsequent periods to reflect final grant amounts. For employees and consultants who are working on specific capital projects, the share-based compensation is allocated to projects under development. For the remainder of employees and consultants, the compensation is expensed.
Decommissioning liabilities	[l] Decommissioning liabilities The Company records a liability for the reclamation of its exploration and evaluation interests based on the best estimate of costs for site closure and reclamation activities that the Company is legally or constructively required to remediate, and the liability is recognized at the time the environmental disturbance occurs. The resulting costs are capitalized to the corresponding asset. The fair value of the provision for closure and reclamation liabilities is estimated using expected cash flows, based on engineering and environmental reports prepared by third party industry specialists, discounted at a pre-tax rate specific to the liability. The capitalized amount is amortized on the same basis as the related asset. The liability is adjusted for accretion of the discounted obligation and any changes in the amount or timing of the underlying future cash flows. Significant judgments and estimates are involved in forming expectations of the amount and timing of future site closure and reclamation cash flows. Future restoration costs are reviewed annually and any changes in the estimate are reflected in the present value of the provision at the reporting date. WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated
Share capital	[m] Share capital The Company records proceeds from share issuances net of issuance costs. Shares issued for consideration other than cash are valued at the quoted price on the date the shares are issued.
Financial instruments	[n] Financial instruments The Company’s classification of its financial instruments is as follows: Asset or Liability Classification Cash Held-for-trading Amounts receivable Amortized cost Accounts payable Amortized cost Due to related parties Amortized cost Promissory note and convertible debenture Amortized cost Derivative liability Fair value through profit and loss (“FVTPL”) The fair value hierarchy under US GAAP is based on the following three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2: Observable inputs other than Level I, quoted prices for similar assets or liabilities in active prices whose inputs are observable or whose significant value drivers are observable; and Level 3: Assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s derivative liability is based on Level 3 inputs in the ASC 820 fair value hierarchy. . Derivative Liabilities The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. The Company uses the Black-Scholes Option Pricing Model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Oct. 31, 2021
Accounting Policies [Abstract]
SCHEDULE OF DEPRECIATION RATE	Depreciation is provided at rates calculated to write off the cost of PP&E, less their estimated residual value. The depreciation rates and method applicable to each category of property, plant and equipment are as follows: SCHEDULE OF DEPRECIATION RATE Class Rate Computer equipment 55% declining balance Furniture 20% declining balance Plant equipment 20% declining balance Furnace To be determined Leasehold improvement Term of lease Right-of-use assets Term of lease

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Oct. 31, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT Computer Equipment Furniture Leasehold Improvement Furnace & Plant Equipment Total $ $ $ $ $ Cost Balance, October 31, 2019 22,632 33,584 5,850 27,897 89,963 Additions 9,852 5,672 1,810 838 18,172 Foreign exchange effect (166 ) (340 ) (50 ) (322 ) (878 ) Balance, October 31, 2020 32,318 38,916 7,610 28,413 107,257 Cost, Beginning Balance 32,318 38,916 7,610 28,413 107,257 Additions 77,955 11,510 129,257 2,278,205 2,496,927 Write-off of equipment (4,245 ) – – – (4,245 ) Foreign exchange effect 3,601 3,116 2,614 38,108 47,439 Balance, October 31, 2021 109,629 53,542 139,481 2,344,726 2,647,378 Cost, Ending Balance 109,629 53,542 139,481 2,344,726 2,647,378 Accumulated Depreciation Balance, October 31, 2019 3,184 1,679 1,950 – 6,813 Depreciation expense 11,412 6,598 2,861 – 20,871 Foreign exchange effect 81 49 7 – 137 Balance, October 31, 2020 14,677 8,326 4,818 – 27,821 Accumulated Depreciation, Beginning Balance 14,677 8,326 4,818 – 27,821 Depreciation expense 13,907 7,443 8,827 13,971 44,148 Write-off of equipment (2,057 ) – – – (2,057 ) Foreign exchange effect 1,294 745 502 221 2,762 Balance, October 31, 2021 27,821 16,514 14,147 14,192 72,674 Accumulated Depreciation, Ending Balance 27,821 16,514 14,147 14,192 72,674 Net Book Value Balance, October 31, 2020 17,641 30,590 2,792 28,413 79,436 Balance, October 31, 2021 81,808 37,028 125,334 2,330,534 2,574,704 Net Book Value 81,808 37,028 125,334 2,330,534 2,574,704

RIGHT-OF-USE ASSETS (Tables)

RIGHT-OF-USE ASSETS (Tables)	12 Months Ended
	Oct. 31, 2021
Right-of-use Assets
SCHEDULE OF RIGHT-OF-USE ASSETS	SCHEDULE OF RIGHT-OF-USE ASSETS Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Cost Balance, October 31, 2019 – – – – – Initial adoption of ASU 2016-02 60,418 – 23,131 – 83,549 Additions – – – 354,263 354,263 Foreign exchange effect (717 ) – (275 ) 3,686 2,694 Balance, October 31, 2020 59,701 – 22,856 357,949 440,506 Operating lease right-of-use asset, cost, beginning balance 59,701 – 22,856 357,949 440,506 Additions 91,237 287,847 – – 379,084 Foreign exchange effect 5,943 4,544 1,724 26,997 39,208 Balance, October 31, 2021 156,881 292,391 24,580 384,946 858,798 Operating lease right-of-use asset, cost, ending balance 156,881 292,391 24,580 384,946 858,798 Accumulated Depreciation Balance, October 31, 2019 – – – – – Depreciation expense 41,708 – 14,286 9,841 65,835 Foreign exchange effect 434 – 148 102 684 Balance, October 31, 2020 42,142 – 14,434 9,943 66,519 Operating lease right-of-use asset, accumulated depreciation, beginning balance 42,142 – 14,434 9,943 66,519 Depreciation expense 44,259 15,288 8,915 117,292 185,754 Foreign exchange effect 3,876 241 1,231 2,602 7,950 Balance, October 31, 2021 90,277 15,529 24,580 129,837 260,223 Operating lease right-of-use asset, accumulated depreciation, ending balance 90,277 15,529 24,580 129,837 260,223 Net Book Value Balance, October 31, 2020 17,559 – 8,422 348,006 373,987 Balance, October 31, 2021 66,604 276,862 – 255,109 598,575 Operating lease right-of-use asset 66,604 276,862 – 255,109 598,575

LEASE OBLIGATIONS (Tables)

LEASE OBLIGATIONS (Tables)	12 Months Ended
	Oct. 31, 2021
Lease Obligations
SCHEDULE OF OPERATING LEASE	SCHEDULE OF OPERATING LEASE Vancouver Office Virginia Office Nevada Office Pilot Plant Total $ $ $ $ $ Balance, October 31, 2019 – – – – – Initial adoption of ASU 2016-02 60,418 – 23,131 – 83,549 Additions – – – 354,263 354,263 Lease payments (43,627 ) – (14,990 ) (10,831 ) (69,448 ) Interest expenses 2,477 – 1,005 3,551 7,033 Foreign exchange effect (1,145 ) – 3,065 3,610 5,530 Balance, October 31, 2020 18,123 – 12,211 350,593 380,927 Additions 91,237 260,649 – – 351,886 Lease payments (47,931 ) (5,137 ) (9,457 ) (139,037 ) (201,562 ) Interest expenses 3,076 3,019 219 19,005 25,319 Prior period adjustment – – (3,065 ) – (3,065 ) Foreign exchange effect 2,099 4,081 92 24,548 30,820 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325 Which consist of: Current lease obligation 46,270 16,328 – 129,447 192,045 Non-current lease obligation 20,334 246,284 – 125,662 392,280 Balance, October 31, 2021 66,604 262,612 – 255,109 584,325

MINERAL PROPERTY COSTS (Tables)

MINERAL PROPERTY COSTS (Tables)	12 Months Ended
	Oct. 31, 2021
Extractive Industries [Abstract]
SCHEDULE OF MINERAL PROPERTY COSTS	SCHEDULE OF MINERAL PROPERTY COSTS Beaverdell Property Silverado Property Tami Mosi Total $ $ $ $ Balance, October 31, 2019 1 1 93,452 93,454 Sale of mineral property (1 ) – – (1 ) Balance, October 31, 2020 and 2021 – 1 93,452 93,453 Sale of mineral property - – – - Balance, October 31, 2020 and 2021 – 1 93,452 93,453

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Oct. 31, 2021
Related Party Transactions [Abstract]
SCHEDULE OF DUE TO RELATED PARTIES	SCHEDULE OF DUE TO RELATED PARTIES October 31, 2021 October 31, 2020 $ $ Wages payable to directors and officers 357,500 161,922 Benefits payable to directors and officers 539,209 – Fees and expenses payable to directors and officers 127,878 682,068 Interests due to a shareholder 2,230 – Total 1,026,817 843,990

CONVERTIBLE DEBENTURE (Tables)

CONVERTIBLE DEBENTURE (Tables)	12 Months Ended
	Oct. 31, 2021
Debt Disclosure [Abstract]
SCHEDULE OF OPTION PRICING MODEL	The inputs used in the Black-Scholes Option Pricing Model are as follows: SCHEDULE OF OPTION PRICING MODEL October 31, June 15, July 27, 2021 2021 2020 Risk free rate of interest 1.08 % 0.31 % 0.26 % Expected life in years 1.11 1.50 0.74 Conversion exercise price $ 0.10 $ 0.10 CA$ 0.15 Underlying share price of the Company CA$ 0.73 CA$ 0.23 CA$ 0.13 Expected volatility 107.62 % 87.17 % 82.54 % Expected dividend rate Nil Nil Nil
SCHEDULE OF DERIVATIVE INSTRUMENTS	SCHEDULE OF DERIVATIVE INSTRUMENTS July 2020 Convertible Debenture June 2021 Convertible Debenture July 2021 Convertible Debenture Total $ $ $ $ Debt Host Liability Balance, October 31, 2019 – – – – Value of debt host liability recognized 87,083 – – 87,083 Accretion and interest expense 8,751 – – 8,751 Foreign currency translation 484 – – 484 Balance, October 31, 2020 96,318 – – 96,318 Value of debt host liability recognized – 1 – 1 Accretion and interest expense 23,587 43 63 23,693 Conversion (125,560 ) – – (125,560 ) Foreign currency translation 5,655 – – 5,655 Balance, October 31, 2021 – 44 63 107 Embedded Derivative Liability Balance, October 31, 2019 – – – – Fair value of embedded derivative liability recognized 25,041 – – 25,041 Fair value adjustment (4,979 ) – – (4,979 ) Foreign currency translation 61 – – 61 Balance, October 31, 2020 20,123 – – 20,123 Fair value of embedded derivative liability recognized – 1,646,600 – 1,646,600 Fair value adjustment (16,058 ) 5,717,328 – 5,701,270 Conversion (5,247 ) – – (5,247 ) Foreign currency translation 1,182 85,772 – 86,954 Balance, October 31, 2021 – 7,449,700 – 7,449,700 Combined Value of Convertible Debenture Balance, October 31, 2019 – – – – Conversion – – – – Balance, October 31, 2020 116,441 – – 116,441 Conversion – – – – Balance, October 31, 2021 – 7,449,744 63 7,449,807 WESTERN MAGNESIUM CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Expressed in US Dollars, except where otherwise indicated

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	12 Months Ended
	Oct. 31, 2021
Equity [Abstract]
SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS	A summary of the changes in the Company’s common share purchase warrants during the year ended October 31, 2021 are as follows: SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS Expiry Date Exercise Price (CA$) Weighted Average Life (Years) October 31, Granted Exercised Expired/ Cancelled October 31, 2021 August 31, 2021* 0.21 – 3,643,791 - (3,118,618 ) (525,173 ) – November 22, 2021 0.19 0.14 – 5,599,171 (1,439,150 ) – 4,160,021 January 17, 2022 0.19 0.29 – 7,337,914 (70,000 ) – 7,267,914 January 31, 2022 0.19 0.33 – 5,382,303 – – 5,382,303 February 21, 2022 0.05 0.39 1,505,200 – – – 1,505,200 March 24, 2022 0.19 0.48 – 6,554,172 (212,300 ) – 6,341,872 March 27, 2022 0.05 0.49 1,482,025 – (500,000 ) – 982,025 April 27, 2022 0.19 0.57 – 851,395 (60,000 ) – 791,395 May 9, 2022 0.05 0.61 2,368,626 – (554,901 ) – 1,813,725 May 30, 2022 0.19 0.66 – 5,223,420 – – 5,223,420 June 17, 2022 0.19 0.71 – 17,853,506 (150,000 ) – 17,703,506 July 18, 2022 0.30 0.79 – 4,350,000 – – 4,350,000 August 14, 2022 0.05 0.87 1,110,000 – (910,000 ) – 200,000 February 13, 2023 0.65 1.37 – 3,827,601 – – 3,827,601 Total 10,109,642 56,979,482 (7,014,969 ) (525,173 ) 59,548,982 Weighted average exercise price CA$ 0.11 CA$ 0.23 CA$ 0.16 CA$ 0.21 CA$ 0.22 * The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791 warrants, extending the expiry date from January 17, 2021 to August 31, 2021, subject to acceleration if the closing price of the Company’s shares exceeds CA$ 0.30 per common share for at least 10 consecutive trading days. A summary of the changes in the Company’s common share purchase warrants during the year ended October 31, 2020 are as follows: Expiry Date Exercise Price Weighted Average Life (Years) October 31, 2019 Granted Exercised Expired/ Cancelled October 31, 2020 January 17, 2021 0.21 – – 3,643,791 – – 3,643,791 February 21, 2022 0.05 2.31 1,505,200 – – – 1,505,200 March 27, 2022 0.05 2.41 3,426,025 – (1,944,000 ) – 1,482,025 May 9, 2022 0.05 2.52 5,088,626 – (2,720,000 ) – 2,368,626 August 14, 2022 0.05 2.79 1,310,000 – (200,000 ) – 1,110,000 May 7, 2020* 0.07 – 3,100,000 – (3,000,000 ) (100,000 ) – October 4, 2020* 0.08 – 5,016,000 – (3,425,000 ) (1,591,000 ) – November 30, 2020* 0.08 – 6,169,926 – (3,091,383 ) (3,078,543 ) – January 23, 2021* 0.08 – 6,388,435 – (3,409,160 ) (2,979,275 ) – March 29, 2021* 0.08 – 8,188,046 – (4,496,710 ) (3,691,336 ) – May 13, 2021* 0.08 – 31,404,738 – (18,050,408 ) (13,354,330 ) – Total 71,596,996 3,643,791 (40,336,661 ) (24,794,484 ) 10,109,642 Weighted average exercise price CA$ 0.07 CA$ 0.21 CA$ 0.08 CA$ 0.08 CA$ 0.11 * On December 20, 2019, the Company exercised its right to call, subject to acceleration provisions, all outstanding warrants set to expire between May 7, 2020 and May 13, 2021. The expiry was amended to January 19, 2020. This expiry date was then extended to February 19, 2020. Any unexercised warrants were voided and of no value after February 19, 2020.
SCHEDULE OF ASSUMPTIONS USED	SCHEDULE OF ASSUMPTIONS USED 2021 2020 Risk free rate of interest 0.20 1.07 % 0.43 1.51 % Expected life of options 2 5 5 Exercise price of options CA$ 0.13 0.70 CA$ 0.11 0.16 Expected annualized volatility 130.88 140.05 % 120.13 188.46 % Expected dividend rate Nil Nil
SCHEDULE OF STOCK OPTIONS ACTIVITY	A summary of the changes in the Company’s stock options during the year ended October 31, 2021 are as follows: SCHEDULE OF STOCK OPTIONS ACTIVITY Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2020 Granted Exercised Expired/ Cancelled Outstanding as at October 31, 2021 Vested as at October 31, 2021 February 11, 2021 0.05 – 800,000 – – (800,000 ) – – August 16, 2021 0.05 – 600,000 – (600,000 ) – – – March 27, 2022 0.05 0.40 1,750,000 – (250,000 ) – 1,500,000 1,500,000 August 26, 2022 0.13 – 500,000 – – (500,000 ) – – December 30, 2022 0.13 1.16 – 6,150,000 (100,000 ) (50,000 ) 6,000,000 5,837,500 April 19, 2023 0.05 – 800,000 – – (800,000 ) – – August 12, 2023 0.05 1.78 3,120,000 – (600,000 ) (230,000 ) 2,290,000 2,290,000 December 3, 2023 0.05 2.09 7,000,000 – (550,000 ) – 6,450,000 6,450,000 May 22, 2024 0.12 2.56 7,950,000 – – (50,000 ) 7,900,000 7,900,000 November 3, 2024 0.15 3.01 700,000 – – – 700,000 700,000 November 24, 2024 0.16 3.07 900,000 – (30,000 ) (550,000 ) 320,000 320,000 March 26, 2025 0.11 3.40 300,000 – (200,000 ) – 100,000 100,000 April 23, 2025 0.12 3.48 4,000,000 – (300,000 ) (350,000 ) 3,350,000 3,350,000 December 30, 2025 0.13 4.17 – 9,500,000 – – 9,500,000 9,500,000 August 30, 2026 0.70 4.83 – 21,700,000 – – 21,700,000 21,400,000 October 1, 2026 0.50 4.92 – 1,450,000 – – 1,450,000 1,450,000 Total 28,420,000 38,800,000 (2,630,000 ) (3,330,000 ) 61,260,000 60,797,500 Weighted average exercise price CA$0.09 CA$0.46 CA$0.07 CA$0.09 CA$0.33 CA$0.32 Aggregate intrinsic value $ 19,994,025 $ 19,908,026 Weighted average remaining life 3.46 3.46 Expiry Date Exercise Price Weighted Average Life (Years) Outstanding as at October 31, 2019 Granted Exercised Expired/ Cancelled Outstanding as at October 31, 2020 Vested as at October 31, 2020 May 31, 2020 0.08 – 400,000 – (400,000 ) – – – June 3, 2020 0.05 – 550,000 – – (550,000 ) – – February 11, 2021 0.05 0.53 1,300,000 – – (500,000 ) 800,000 800,000 August 16, 2021 0.05 1.04 1,200,000 – – (600,000 ) 600,000 600,000 March 27, 2022 0.05 1.65 2,000,000 – – (250,000 ) 1,750,000 1,750,000 August 26, 2022 0.13 – – 500,000 – – 500,000 – April 19, 2023 0.05 2.72 800,000 – – – 800,000 800,000 August 12, 2023 0.05 3.03 3,780,000 – (100,000 ) (560,000 ) 3,120,000 3,120,000 December 3, 2023 0.05 3.35 9,600,000 – – (2,600,000 ) 7,000,000 7,000,000 May 22, 2024 0.12 3.81 10,000,000 – – (2,050,000 ) 7,950,000 7,950,000 November 3, 2024 0.15 4.27 – 700,000 – – 700,000 700,000 November 24, 2024 0.16 4.32 – 900,000 – – 900,000 775,000 March 26, 2025 0.11 4.66 – 300,000 – – 300,000 300,000 April 23, 2025 0.12 4.73 – 4,200,000 – (200,000 ) 4,000,000 3,625,000 Total 29,630,000 6,600,000 (500,000 ) (7,310,000 ) 28,420,000 27,420,000 Weighted average exercise price CA$0.07 CA$0.13 CA$0.07 CA$0.07 CA$0.09 CA$0.09 Aggregate intrinsic value $ 801,922 $ 866,441 Weighted average remaining life 3.18 3.18
SCHEDULE OF NONVESTED STOCK OPTIONS	A summary of the changes in the Company’s nonvested stock options during the year ended October 31, 2021 are as follows: SCHEDULE OF NONVESTED STOCK OPTIONS Expiry Date Fair Value Per Share Weighted Average Life (Years) Nonvested as at October 31, 2020 Granted Vested Expired/ Cancelled Nonvested as at October 31, 2021 December 30, 2022 0.07 1.16 – 650,000 487,500 – 162,500 August 30, 2026 0.56 4.83 – 300,000 – – 300,000 Total – 950,000 487,500 – 462,500 Weighted average grant date fair value – per option – CA$0.22 CA$0.07 – CA$0.39 Weighted average grant date fair value – total – $ 170,781 $ 26,650 – $ 144,131

FINANCIAL INSTRUMENTS AND FIN_2

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Tables)	12 Months Ended
	Oct. 31, 2021
Fair Value Disclosures [Abstract]
SCHEDULE OF CLASSIFICATION OF ITS FINANCIAL INSTRUMENTS	The Company’s classification of its financial instruments is as follows: SCHEDULE OF CLASSIFICATION OF ITS FINANCIAL INSTRUMENTS Financial Instruments Measurement Method Associated Risk Fair Value at October 31, 2021 ($) Cash FVTPL Credit and currency 462,360 Amounts receivable Amortized cost Credit and currency 151,485 Deposits held by related parties Amortized cost Credit and currency 486,462 Accounts payable and accrued liabilities Amortized cost Currency 1,989,316 Due to related parties Amortized cost Currency 1,026,817 Convertible debenture Amortized cost Currency 107 Convertible debenture - derivative liability FVTPL Currency 7,449,700
SCHEDULE OF FOREIGN CURRENCY RISK	SCHEDULE OF FOREIGN CURRENCY RISK October 31, 2021 $ Cash 186,627 Deposits held by related parties 486,462 Accounts payable and accrued liabilities (773,011 ) Due to related parties (467,500 ) Convertible debenture (1,500,000 ) Total (2,067,422 )

SEGMENTED INFORMATION (Tables)

SEGMENTED INFORMATION (Tables)	12 Months Ended
	Oct. 31, 2021
Segment Reporting [Abstract]
SCHEDULE OF ASSETS INFORMATION	SCHEDULE OF ASSETS INFORMATION October 31, 2021 October 31, 2020 $ $ Canada – property, plant and equipment 2,546,383 79,436 United States – property, plant and equipment 28,321 – United States – mineral property costs 93,453 93,453 Asset 2,668,157 172,889 Canada – other assets 1,554,827 533,815 United States – other assets 290,528 2,059 1,845,355 535,874 Total Assets 4,513,512 708,763

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Oct. 31, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF EFFECTIVE TAX RATES RECONCILIATION	Significant items resulting in the difference between the Company’s income tax rate and the federal statutory rate are as follows: SCHEDULE OF EFFECTIVE TAX RATES RECONCILIATION 2021 2020 $ $ Loss for the year (23,549,612 ) (4,672,605 ) Effective statutory rate 33.02 % 31.21 % Expected income tax recovery at statutory rate (7,778,880 ) (1,458,320 ) Net adjustment for deductible and non-deductible amounts 2,636,262 250,196 Foreign exchange effect (9,867 ) (175,597 ) Valuation allowance 5,152,485 1,383,721 Deferred income tax provision (recovery) – –
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITY	The Company’s deferred tax assets and liabilities are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITY 2021 2020 $ $ Non-capital loss carry-forwards 5,340,578 2,600,561 Property and equipment (159,673 ) (123,561 ) Lease liability 180,812 103,789 Convertible debenture (509,985 ) – Convertible debenture – derivative liability 2,532,898 – Exploration and evaluation asset 359,700 - Share issue costs - 11,056 Valuation allowance (7,744,330 ) (2,591,845 ) Deferred income tax asset (liability) – –

NATURE OF OPERATIONS AND GOIN_2

NATURE OF OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 52,129,621	$ 28,580,009
Working capital deficit	9,657,316	2,392,189
Comprehensive loss	$ 23,827,678	$ 4,749,411

SCHEDULE OF DEPRECIATION RATE (

SCHEDULE OF DEPRECIATION RATE (Details)	12 Months Ended
	Oct. 31, 2021
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	55% declining balance
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	20% declining balance
Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	20% declining balance
Furnace [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	To be determined
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	Term of lease
Right of Use Assets [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate	Term of lease

SCHEDULE OF PROPERTY, PLANT AND

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Property, Plant and Equipment [Line Items]
Cost, Beginning Balance	$ 107,257	$ 89,963
Additions	2,496,927	18,172
Foreign exchange effect	47,439	(878)
Write-off of equipment	(4,245)
Cost, Ending Balance	2,647,378	107,257
Accumulated Depreciation, Beginning Balance	27,821	6,813
Depreciation expense	44,148	20,871
Foreign exchange effect	2,762	137
Write-off of equipment	(2,057)
Accumulated Depreciation, Ending Balance	72,674	27,821
Net Book Value	2,574,704	79,436
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost, Beginning Balance	32,318	22,632
Additions	77,955	9,852
Foreign exchange effect	3,601	(166)
Write-off of equipment	(4,245)
Cost, Ending Balance	109,629	32,318
Accumulated Depreciation, Beginning Balance	14,677	3,184
Depreciation expense	13,907	11,412
Foreign exchange effect	1,294	81
Write-off of equipment	(2,057)
Accumulated Depreciation, Ending Balance	27,821	14,677
Net Book Value	81,808	17,641
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Cost, Beginning Balance	38,916	33,584
Additions	11,510	5,672
Foreign exchange effect	3,116	(340)
Write-off of equipment
Cost, Ending Balance	53,542	38,916
Accumulated Depreciation, Beginning Balance	8,326	1,679
Depreciation expense	7,443	6,598
Foreign exchange effect	745	49
Write-off of equipment
Accumulated Depreciation, Ending Balance	16,514	8,326
Net Book Value	37,028	30,590
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost, Beginning Balance	7,610	5,850
Additions	129,257	1,810
Foreign exchange effect	2,614	(50)
Write-off of equipment
Cost, Ending Balance	139,481	7,610
Accumulated Depreciation, Beginning Balance	4,818	1,950
Depreciation expense	8,827	2,861
Foreign exchange effect	502	7
Write-off of equipment
Accumulated Depreciation, Ending Balance	14,147	4,818
Net Book Value	125,334	2,792
Furnace and Plant Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost, Beginning Balance	28,413	27,897
Additions	2,278,205	838
Foreign exchange effect	38,108	(322)
Write-off of equipment
Cost, Ending Balance	2,344,726	28,413
Accumulated Depreciation, Beginning Balance
Depreciation expense	13,971
Foreign exchange effect	221
Write-off of equipment
Accumulated Depreciation, Ending Balance	14,192
Net Book Value	$ 2,330,534	$ 28,413

SCHEDULE OF RIGHT-OF-USE ASSETS

SCHEDULE OF RIGHT-OF-USE ASSETS (Details) - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Operating lease right-of-use asset, cost, beginning balance	$ 440,506
Initial adoption of ASU 2016-02		83,549
Additions	379,084	354,263
Foreign exchange effect	39,208	2,694
Operating lease right-of-use asset, cost, ending balance	858,798	440,506
Operating lease right-of-use asset, accumulated depreciation, beginning balance	66,519
Depreciation expense	185,754	65,835
Foreign exchange effect	7,950	684
Operating lease right-of-use asset, accumulated depreciation, ending balance	260,223	66,519
Operating lease right-of-use asset	598,575	373,987
Vancouver Office [Member]
Operating lease right-of-use asset, cost, beginning balance	59,701
Initial adoption of ASU 2016-02		60,418
Additions	91,237
Foreign exchange effect	5,943	(717)
Operating lease right-of-use asset, cost, ending balance	156,881	59,701
Operating lease right-of-use asset, accumulated depreciation, beginning balance	42,142
Depreciation expense	44,259	41,708
Foreign exchange effect	3,876	434
Operating lease right-of-use asset, accumulated depreciation, ending balance	90,277	42,142
Operating lease right-of-use asset	66,604	17,559
Virginia Office [Member]
Operating lease right-of-use asset, cost, beginning balance
Initial adoption of ASU 2016-02
Additions	287,847
Foreign exchange effect	4,544
Operating lease right-of-use asset, cost, ending balance	292,391
Operating lease right-of-use asset, accumulated depreciation, beginning balance
Depreciation expense	15,288
Foreign exchange effect	241
Operating lease right-of-use asset, accumulated depreciation, ending balance	15,529
Operating lease right-of-use asset	276,862
Nevada Office [Member]
Operating lease right-of-use asset, cost, beginning balance	22,856
Initial adoption of ASU 2016-02		23,131
Additions
Foreign exchange effect	1,724	(275)
Operating lease right-of-use asset, cost, ending balance	24,580	22,856
Operating lease right-of-use asset, accumulated depreciation, beginning balance	14,434
Depreciation expense	8,915	14,286
Foreign exchange effect	1,231	148
Operating lease right-of-use asset, accumulated depreciation, ending balance	24,580	14,434
Operating lease right-of-use asset		8,422
Pilot Plant [Member]
Operating lease right-of-use asset, cost, beginning balance	357,949
Initial adoption of ASU 2016-02
Additions		354,263
Foreign exchange effect	26,997	3,686
Operating lease right-of-use asset, cost, ending balance	384,946	357,949
Operating lease right-of-use asset, accumulated depreciation, beginning balance	9,943
Depreciation expense	117,292	9,841
Foreign exchange effect	2,602	102
Operating lease right-of-use asset, accumulated depreciation, ending balance	129,837	9,943
Operating lease right-of-use asset	$ 255,109	$ 348,006

SCHEDULE OF OPERATING LEASE (De

SCHEDULE OF OPERATING LEASE (Details) - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Balance, October 31, 2020	$ 380,927
Initial adoption of ASU 2016-02		83,549
Additions	351,886	354,263
Lease payments	(201,562)	(69,448)
Interest expenses	25,319	7,033
Foreign exchange effect	30,820	5,530
Prior period adjustment	(3,065)
Balance, October 31, 2021	584,325	380,927
Current lease obligation	192,045	143,709
Non-current lease obligation	392,280	237,218
Vancouver Office [Member]
Balance, October 31, 2020	18,123
Initial adoption of ASU 2016-02		60,418
Additions	91,237
Lease payments	(47,931)	(43,627)
Interest expenses	3,076	2,477
Foreign exchange effect	2,099	(1,145)
Prior period adjustment
Balance, October 31, 2021	66,604	18,123
Current lease obligation	46,270
Non-current lease obligation	20,334
Virginia Office [Member]
Balance, October 31, 2020
Initial adoption of ASU 2016-02
Additions	260,649
Lease payments	(5,137)
Interest expenses	3,019
Foreign exchange effect	4,081
Prior period adjustment
Balance, October 31, 2021	262,612
Current lease obligation	16,328
Non-current lease obligation	246,284
Nevada Office [Member]
Balance, October 31, 2020	12,211
Initial adoption of ASU 2016-02		23,131
Additions
Lease payments	(9,457)	(14,990)
Interest expenses	219	1,005
Foreign exchange effect	92	3,065
Prior period adjustment	(3,065)
Balance, October 31, 2021		12,211
Current lease obligation
Non-current lease obligation
Pilot Plant [Member]
Balance, October 31, 2020	350,593
Initial adoption of ASU 2016-02
Additions		354,263
Lease payments	(139,037)	(10,831)
Interest expenses	19,005	3,551
Foreign exchange effect	24,548	3,610
Prior period adjustment
Balance, October 31, 2021	255,109	$ 350,593
Current lease obligation	129,447
Non-current lease obligation	$ 125,662

LEASE OBLIGATIONS (Details Narr

LEASE OBLIGATIONS (Details Narrative) - USD ($)	Oct. 31, 2021	Oct. 31, 2020	Nov. 02, 2019	Oct. 31, 2019
Lease liability	$ 584,325	$ 380,927	$ 83,549
Borrowing rate			7.00%
British Columbia [Member]
Lease liability	$ 91,237	$ 354,263
Borrowing rate	7.00%	6.00%
McLean,Virginia [Member]
Lease liability	$ 260,649
Borrowing rate	7.00%

SCHEDULE OF MINERAL PROPERTY CO

SCHEDULE OF MINERAL PROPERTY COSTS (Details) - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Balance, ending	$ 93,453	$ 93,454
Sale of mineral property		(1)
Balance, ending	93,453	93,453
Beaverdell Property [Member]
Balance, ending		1
Sale of mineral property		(1)
Balance, ending
Silverado Property [Member]
Balance, ending	1	1
Sale of mineral property
Balance, ending	1	1
TamiMosi Property [Member]
Balance, ending	93,452	93,452
Sale of mineral property
Balance, ending	$ 93,452	$ 93,452

MINERAL PROPERTY COSTS (Details

MINERAL PROPERTY COSTS (Details Narrative)	Apr. 07, 2020USD ($)	Oct. 31, 2021USD ($)a	Oct. 31, 2021CAD ($)a	Oct. 31, 2020USD ($)
Beaverdell Property [Member]
Ownership percentage		100.00%	100.00%
Sale of stock ownership interest percentage				100.00%
Aggregate proceeds from sale of property amount		$ 37,157	$ 50,000
Recognized gain on sale of property	$ 37,156
Carrying value of property				$ 1
Silverado Property [Member]
Ownership percentage		100.00%	100.00%
Carrying value of property				$ 1
TamiMosi Property [Member]
Ownership percentage		2.00%	2.00%
Sale of stock ownership interest percentage		100.00%	100.00%
Number of acres located | a		1,637	1,637

SCHEDULE OF DUE TO RELATED PART

SCHEDULE OF DUE TO RELATED PARTIES (Details) - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Related Party Transactions [Abstract]
Wages payable to directors and officers	$ 357,500	$ 161,922
Benefits payable to directors and officers	539,209
Fees and expenses payable to directors and officers	127,878	682,068
Interests due to a shareholder	2,230
Total	$ 1,026,817	$ 843,990

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)	12 Months Ended
	Oct. 31, 2021USD ($)	Oct. 31, 2021CAD ($)	Oct. 31, 2020USD ($)	Oct. 31, 2020CAD ($)
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Director and officer aggregate amount	$ 987,912
Costs and expenses related party	696,431
Related party transaction remaining balance	291,481
Deposit held related parties	486,462
Due to related parties	1,026,817		$ 843,990
Key management compensation expenses	2,900,000
Salaries management and consulting fees	3,020,102		1,785,032
Consulting fees	95,390	$ 120,000	35,771	$ 45,000
Director and officer	20,000
Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Director and officer aggregate amount	2,292,912
Costs and expenses related party	2,097,931
Related party transaction remaining balance	194,981
Directors and Officers [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Directors officers and related parties stock based compensation	$ 10,248,013		$ 300,211

CONTINGENT LIABILITIES AND CO_2

CONTINGENT LIABILITIES AND COMMITMENTS (Details Narrative)	Feb. 08, 2021USD ($)shares	Feb. 08, 2021CAD ($)shares	Dec. 31, 2020USD ($)	Dec. 31, 2020CAD ($)	Dec. 30, 2020USD ($)	Dec. 30, 2020CAD ($)	Sep. 29, 2020USD ($)	Sep. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021CAD ($)	Oct. 31, 2021USD ($)$ / sharesshares	Oct. 31, 2021CAD ($)	Oct. 31, 2020USD ($)$ / sharesshares	Oct. 31, 2020CAD ($)	Nov. 03, 2021USD ($)shares	Nov. 03, 2021CAD ($)$ / sharesshares	Jun. 07, 2021USD ($)shares	Jun. 07, 2021CAD ($)shares	May 18, 2021shares	Apr. 19, 2021USD ($)	Mar. 11, 2021CAD ($)	Jan. 13, 2021$ / shares	Sep. 12, 2018	Aug. 28, 2018USD ($)	Nov. 01, 2016USD ($)	Nov. 01, 2016CAD ($)$ / shares
Loss Contingencies [Line Items]
Loss contingency damages	$ 3,900,000	$ 4,900,000	$ 3,400,000	$ 4,200,000
Payment termination amount					$ 76,588	$ 102,001
Outstanding amount payable											$ 53,491
Commitment of cash or arrangments amount																									$ 1,800
Commitment of cash or arrangments amount cash																										$ 2,500
Number of shares issued price per share | $ / shares																										$ 0.05
Cash											21,600
Sublease Income									$ 7,909	$ 9,794			$ 16,727	$ 20,715
Payments for (Proceeds from) Tenant Allowance											$ 41,010
Percentage of issued and outstanding common shares																							5.00%
Common stock outstanding																								$ 5,000,000
Common stock shares issued | shares											392,943,398		323,419,527		9,163,425	9,163,425	1,538,461	1,538,461	1,360,959
Common share price per share | (per share)											$ 0.001		$ 0.001			$ 0.65						$ 0.30
Fair value of equivalents															$ 4,796,832	$ 5,956,226	$ 305,832	$ 369,231			$ 5,956,226
Lampert Agreement [Member]
Loss Contingencies [Line Items]
Outstanding amount payable																				$ 367,227
Percentage of interest rate owned																				9.00%
Lease Agreement [Member]
Loss Contingencies [Line Items]
Sublease Income								$ 9,113
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency damages							$ 2,500,000
Warrant to purchase connon stock shares | shares	33,000,000	33,000,000
Issuance of share based minimum requirement											$ 1,800	$ 2,500

PROMISSORY NOTE (Details Narrat

PROMISSORY NOTE (Details Narrative)	1 Months Ended				12 Months Ended
	Oct. 31, 2020USD ($)	Oct. 31, 2020CAD ($)	Oct. 31, 2019USD ($)	Oct. 31, 2019CAD ($)	Oct. 31, 2021USD ($)	Oct. 31, 2020USD ($)
Related party loan			$ 112,895	$ 150,000
Percentage of unsecured loan interest			18.00%	18.00%
Accrued interest promissory note					$ 1,639	$ 16,655
Repayment of promissory note interest					65,761	56,478
Outstanding notes payable					53,491
Promissory Note [Member]
Repayment of promissory note interest					65,761	101,066
Outstanding notes payable	$ 60,567					$ 60,567
Minimum [Member]
Additional increase in promissory note loan	44,588	$ 60,000
Maximum [Member]
Additional increase in promissory note loan	$ 157,483	$ 210,000

PROVISION FOR FLOW THROUGH SH_2

PROVISION FOR FLOW THROUGH SHARE ISSUANCES (Details Narrative) - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Provision For Flow Through Share Issuances
Provision for tax and related obligations	$ 233,285	$ 216,924

SCHEDULE OF OPTION PRICING MODE

SCHEDULE OF OPTION PRICING MODEL (Details)	12 Months Ended
	Oct. 31, 2021$ / shares	Oct. 31, 2020	Oct. 31, 2021$ / shares
Short-term Debt [Line Items]
Expected life in years		5 years
Expected dividend rate
October 31, 2021 [Member]
Short-term Debt [Line Items]
Risk free rate of interest	1.08%
Expected life in years	1 year 1 month 9 days
Conversion exercise price	$ 0.10
Underlying share price of the Company			$ 0.73
Expected volatility	107.62%
Expected dividend rate
June 15, 2021 [Member]
Short-term Debt [Line Items]
Risk free rate of interest	0.31%
Expected life in years	1 year 6 months
Conversion exercise price	$ 0.10
Underlying share price of the Company			0.23
Expected volatility	87.17%
Expected dividend rate
July 27, 2021 [Member]
Short-term Debt [Line Items]
Risk free rate of interest	0.26%
Expected life in years	8 months 26 days
Conversion exercise price			0.15
Underlying share price of the Company			$ 0.13
Expected volatility	82.54%
Expected dividend rate

SCHEDULE OF DERIVATIVE INSTRUME

SCHEDULE OF DERIVATIVE INSTRUMENTS (Details) - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Short-term Debt [Line Items]
Balance, October 31, 2020	$ 96,318
Accretion and interest expense	74,319	$ 60,638
Foreign currency translation	(278,066)	(76,806)
Balance, October 31, 2021	107	96,318
Fair value of embedded derivative liability recognized	25,041
Fair value adjustment	(5,701,270)	4,979
Debt Host Liability [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020	96,318
Value of debt host liability recognized	1	87,083
Accretion and interest expense	23,693	8,751
Foreign currency translation	5,655	484
Conversion	(125,560)
Balance, October 31, 2021	107	96,318
Debt Host Liability [Member] | July 2020 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020	96,318
Value of debt host liability recognized		87,083
Accretion and interest expense	23,587	8,751
Foreign currency translation	5,655	484
Conversion	(125,560)
Balance, October 31, 2021		96,318
Debt Host Liability [Member] | June 2021 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020
Value of debt host liability recognized	1
Accretion and interest expense	43
Foreign currency translation
Conversion
Balance, October 31, 2021	44
Debt Host Liability [Member] | July 2021 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020
Value of debt host liability recognized
Accretion and interest expense	63
Foreign currency translation
Conversion
Balance, October 31, 2021	63
Embedded Derivative Liability [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020	20,123
Foreign currency translation	86,954	61
Balance, October 31, 2021	7,449,700	20,123
Fair value of embedded derivative liability recognized	1,646,600	25,041
Fair value adjustment	5,701,270	(4,979)
Conversion	(5,247)
Debt Conversion, Original Debt, Amount	5,247
Embedded Derivative Liability [Member] | July 2020 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020	20,123
Foreign currency translation	1,182	61
Balance, October 31, 2021		20,123
Fair value of embedded derivative liability recognized		25,041
Fair value adjustment	(16,058)	(4,979)
Conversion	(5,247)
Debt Conversion, Original Debt, Amount	5,247
Embedded Derivative Liability [Member] | June 2021 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020
Foreign currency translation	85,772
Balance, October 31, 2021	7,449,700
Fair value of embedded derivative liability recognized	1,646,600
Fair value adjustment	5,717,328
Conversion
Debt Conversion, Original Debt, Amount
Embedded Derivative Liability [Member] | July 2021 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020
Foreign currency translation
Balance, October 31, 2021
Fair value of embedded derivative liability recognized
Fair value adjustment
Conversion
Debt Conversion, Original Debt, Amount
Combined Value of Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020	116,441
Balance, October 31, 2021	7,449,807	116,441
Conversion
Debt Conversion, Original Debt, Amount
Combined Value of Convertible Debenture [Member] | July 2020 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020	116,441
Balance, October 31, 2021		116,441
Conversion
Debt Conversion, Original Debt, Amount
Combined Value of Convertible Debenture [Member] | June 2021 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020
Balance, October 31, 2021	7,449,744
Conversion
Debt Conversion, Original Debt, Amount
Combined Value of Convertible Debenture [Member] | July 2021 Convertible Debenture [Member]
Short-term Debt [Line Items]
Balance, October 31, 2020
Balance, October 31, 2021	63
Conversion
Debt Conversion, Original Debt, Amount

CONVERTIBLE DEBENTURE (Details

CONVERTIBLE DEBENTURE (Details Narrative)	Nov. 03, 2021$ / sharesshares	Nov. 03, 2021$ / sharesshares	Oct. 31, 2021USD ($)$ / sharesshares	Oct. 31, 2021CAD ($)	Jul. 30, 2021USD ($)	Jul. 30, 2021CAD ($)	Jul. 30, 2021	Jun. 15, 2021CAD ($)shares	May 18, 2021USD ($)shares	Feb. 10, 2022$ / sharesshares	Oct. 31, 2021USD ($)$ / sharesshares	Oct. 31, 2020USD ($)shares	Nov. 02, 2021$ / sharesshares	Oct. 31, 2021CAD ($)$ / sharesshares	Jul. 15, 2021USD ($)	Jul. 15, 2021CAD ($)$ / shares	Jun. 07, 2021$ / sharesshares	Jul. 27, 2020USD ($)	Jul. 27, 2020CAD ($)$ / shares	Feb. 19, 2020$ / shares	Oct. 31, 2019	Nov. 01, 2016$ / shares
Short-term Debt [Line Items]
Debt Instrument, Face Amount			$ 53,491								$ 53,491
Debt Instrument, Interest Rate, Stated Percentage																					18.00%
Debt host liability share, face value | $ / shares																						$ 0.05
Common Stock, Shares, Issued | shares	9,163,425	9,163,425	392,943,398						1,360,959		392,943,398	323,419,527		392,943,398			1,538,461
Conversion of Stock, Shares Issued | shares									263,973
Common Stock, Value, Issued			$ 29,842,167								$ 29,842,167	$ 21,322,022
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 0.05						$ 0.08
Interest expenses incurred			70,521
Debt Conversion, Description											one-half of one Class A common stock purchase warrant, with each whole warrant being exercisable at a price of $0.13 until June 10, 2026, and (iii) one-half of one Class B common stock purchase warrant, with each whole warrant being exercisable at a price of $0.19 until June 10, 2026 (collectively, the “Class A and B Warrants”). In addition, the conversion price for accrued interest is the greater of (i) $0.10 and (ii) the minimum conversion price permitted by the TSX-V at the time of conversion.
Convertible debenture's debt host liability			87,083								$ 87,083
Embedded derivative liability											25,041
Fair value of embedded derivative liability												20,123
Embedded derivative liability combined value			107								$ 107	$ 96,318
Common Stock [Member]
Short-term Debt [Line Items]
Debt host liability share, face value | $ / shares	$ 0.65	$ 0.65															$ 0.24
Number of shares issued | shares											56,979,482	3,643,791
Subsequent Event [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Debt host liability share, face value | $ / shares	$ 0.65	$ 0.65								$ 0.19
Number of shares issued | shares		9,163,425								15,159,448
July 2020 Convertible Debenture [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount																		$ 112,124	$ 150,000
Debt Instrument, Interest Rate, Stated Percentage																		12.00%	12.00%
Debt host liability share, face value | $ / shares																			$ 0.15
Common Stock, Shares, Issued | shares									1,360,959
Conversion of Stock, Shares Issued | shares									263,973
Common Stock, Value, Issued									$ 26,286
Convertible debenture's debt host liability												$ 96,318
Debt Instrument, Interest Rate, Effective Percentage												37.00%
July 2021 Convertible Debenture [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount			79,542								$ 79,542			$ 100,000	$ 79,542	$ 100,000
Debt Instrument, Interest Rate, Stated Percentage															12.00%	12.00%
Conversion price per share | $ / shares																$ 0.12
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 0.20
Interest expenses incurred			$ 5,802	$ 7,299
Debt Instrument, Interest Rate, Basis for Effective Rate							effective interest rate of 1,878%
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 79,542	$ 100,000
June 2021 Convertible Debenture [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount								$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage								12.00%
Debt host liability share, face value | $ / shares			$ 1								$ 1
Maturity date of debt								Dec. 10, 2022
Conversion of Stock, Shares Converted | shares								15,000,000
Convertible debenture's debt host liability			$ 1,500,000								$ 1,500,000
Embedded derivative liability											1,646,600
Fair value of embedded derivative liability			7,449,700								7,449,700
Embedded derivative liability combined value			$ 7,449,744								7,449,744
Loss on recognition of debt liability											$ 146,601
Convertible debenture effective interest rate			1,448								1,448			1,448
June 2021 Convertible Debenture [Member] | Convertible Debenture [Member]
Short-term Debt [Line Items]
Convertible debenture's debt host liability			$ 44								$ 44
June 2021 Convertible Debenture [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Number of shares issued | shares	3,000,000
June 2021 Convertible Debenture [Member] | Subsequent Event [Member] | Common Class A [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 0.13
Number of warrants exercisable | shares													1,500,000
June 2021 Convertible Debenture [Member] | Subsequent Event [Member] | Common Class B [Member]
Short-term Debt [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 0.19
Number of warrants exercisable | shares													1,500,000
June 2021 Convertible Debenture [Member] | Subsequent Event [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Number of shares issued | shares	3,000,000
July 2020 Convertible Debenture [Member]
Short-term Debt [Line Items]
Embedded derivative liability combined value												$ 116,441

SUMMARY OF CHANGES IN COMMON SH

SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS (Details)	12 Months Ended
	Oct. 31, 2021$ / shares$ / sharesshares		Oct. 31, 2021$ / sharesshares		Oct. 31, 2020$ / shares$ / sharesshares		Oct. 31, 2020$ / sharesshares		Feb. 19, 2020$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.05		$ 0.05						$ 0.08
Warrants, Beginning balance	10,109,642		10,109,642		71,596,996		71,596,996
Warrants, granted	56,979,482		56,979,482		3,643,791		3,643,791
Warrants, exercised	(7,014,969)		(7,014,969)		(40,336,661)		(40,336,661)
Warrants, Expired/Cancelled	(525,173)		(525,173)		(24,794,484)		(24,794,484)
Warrants, Ending balance	59,548,982		59,548,982		10,109,642		10,109,642
Warrants, weighted average exercise price outstanding | (per share)	$ 0.11		$ 0.11				$ 0.07
Warrants, weighted average exercise price granted | (per share)	0.23						0.21
Warrants, weighted average exercise price, exercised | (per share)	0.16						0.08
Warrants, weighted average exercise price expired cancelled | (per share)	0.21						0.08
Warrants, weighted average exercise price outstanding | (per share)	$ 0.22				$ 0.11		$ 0.11
August 31, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.21	[1]	$ 0.21	[1]
Warrants weighted average life (Years)	0 years	[1]	0 years	[1]
Warrants, Beginning balance	3,643,791	[1]	3,643,791	[1]
Warrants, granted		[1]		[1]
Warrants, exercised	(3,118,618)	[1]	(3,118,618)	[1]
Warrants, Expired/Cancelled	(525,173)	[1]	(525,173)	[1]
Warrants, Ending balance		[1]		[1]	3,643,791	[1]	3,643,791	[1]
November 22, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.19		$ 0.19
Warrants weighted average life (Years)	1 month 20 days		1 month 20 days
Warrants, Beginning balance
Warrants, granted	5,599,171		5,599,171
Warrants, exercised	(1,439,150)		(1,439,150)
Warrants, Expired/Cancelled
Warrants, Ending balance	4,160,021		4,160,021
January 17, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.19		$ 0.19
Warrants weighted average life (Years)	3 months 14 days		3 months 14 days
Warrants, Beginning balance
Warrants, granted	7,337,914		7,337,914
Warrants, exercised	(70,000)		(70,000)
Warrants, Expired/Cancelled
Warrants, Ending balance	7,267,914		7,267,914
January 31, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.19		$ 0.19
Warrants weighted average life (Years)	3 months 29 days		3 months 29 days
Warrants, Beginning balance
Warrants, granted	5,382,303		5,382,303
Warrants, exercised
Warrants, Expired/Cancelled
Warrants, Ending balance	5,382,303		5,382,303
February 21, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.05		$ 0.05		$ 0.05		$ 0.05
Warrants weighted average life (Years)	4 months 20 days		4 months 20 days		2 years 3 months 21 days		2 years 3 months 21 days
Warrants, Beginning balance	1,505,200		1,505,200		1,505,200		1,505,200
Warrants, granted
Warrants, exercised
Warrants, Expired/Cancelled
Warrants, Ending balance	1,505,200		1,505,200		1,505,200		1,505,200
March 24, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.19		$ 0.19
Warrants weighted average life (Years)	5 months 23 days		5 months 23 days
Warrants, Beginning balance
Warrants, granted	6,554,172		6,554,172
Warrants, exercised	(212,300)		(212,300)
Warrants, Expired/Cancelled
Warrants, Ending balance	6,341,872		6,341,872
March 27, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.05		$ 0.05		$ 0.05		$ 0.05
Warrants weighted average life (Years)	5 months 26 days		5 months 26 days		2 years 4 months 28 days		2 years 4 months 28 days
Warrants, Beginning balance	1,482,025		1,482,025		3,426,025		3,426,025
Warrants, granted
Warrants, exercised	(500,000)		(500,000)		(1,944,000)		(1,944,000)
Warrants, Expired/Cancelled
Warrants, Ending balance	982,025		982,025		1,482,025		1,482,025
April 27, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.19		$ 0.19
Warrants weighted average life (Years)	6 months 25 days		6 months 25 days
Warrants, Beginning balance
Warrants, granted	851,395		851,395
Warrants, exercised	(60,000)		(60,000)
Warrants, Expired/Cancelled
Warrants, Ending balance	791,395		791,395
May 9, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.05		$ 0.05		$ 0.05		$ 0.05
Warrants weighted average life (Years)	7 months 9 days		7 months 9 days		2 years 6 months 7 days		2 years 6 months 7 days
Warrants, Beginning balance	2,368,626		2,368,626		5,088,626		5,088,626
Warrants, granted
Warrants, exercised	(554,901)		(554,901)		(2,720,000)		(2,720,000)
Warrants, Expired/Cancelled
Warrants, Ending balance	1,813,725		1,813,725		2,368,626		2,368,626
May 30, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.19		$ 0.19
Warrants weighted average life (Years)	7 months 28 days		7 months 28 days
Warrants, Beginning balance
Warrants, granted	5,223,420		5,223,420
Warrants, exercised
Warrants, Expired/Cancelled
Warrants, Ending balance	5,223,420		5,223,420
June 17, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.19		$ 0.19
Warrants weighted average life (Years)	8 months 15 days		8 months 15 days
Warrants, Beginning balance
Warrants, granted	17,853,506		17,853,506
Warrants, exercised	(150,000)		(150,000)
Warrants, Expired/Cancelled
Warrants, Ending balance	17,703,506		17,703,506
June 18, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.30		$ 0.30
Warrants weighted average life (Years)	9 months 14 days		9 months 14 days
Warrants, Beginning balance
Warrants, granted	4,350,000		4,350,000
Warrants, exercised
Warrants, Expired/Cancelled
Warrants, Ending balance	4,350,000		4,350,000
August 14, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.05		$ 0.05		$ 0.05		$ 0.05
Warrants weighted average life (Years)	10 months 13 days		10 months 13 days		2 years 9 months 14 days		2 years 9 months 14 days
Warrants, Beginning balance	1,110,000		1,110,000		1,310,000		1,310,000
Warrants, granted
Warrants, exercised	(910,000)		(910,000)		(200,000)		(200,000)
Warrants, Expired/Cancelled
Warrants, Ending balance	200,000		200,000		1,110,000		1,110,000
February 13, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares	$ 0.65		$ 0.65
Warrants weighted average life (Years)	1 year 4 months 13 days		1 year 4 months 13 days
Warrants, Beginning balance
Warrants, granted	3,827,601		3,827,601
Warrants, exercised
Warrants, Expired/Cancelled
Warrants, Ending balance	3,827,601		3,827,601
January 17, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares					$ 0.21		$ 0.21
Warrants weighted average life (Years)					0 years		0 years
Warrants, Beginning balance	3,643,791		3,643,791
Warrants, granted					3,643,791		3,643,791
Warrants, exercised
Warrants, Expired/Cancelled
Warrants, Ending balance					3,643,791		3,643,791
May 7 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares					$ 0.07	[2]	$ 0.07	[2]
Warrants weighted average life (Years)					0 years	[2]	0 years	[2]
Warrants, Beginning balance		[2]		[2]	3,100,000	[2]	3,100,000	[2]
Warrants, granted						[2]		[2]
Warrants, exercised					(3,000,000)	[2]	(3,000,000)	[2]
Warrants, Expired/Cancelled					(100,000)	[2]	(100,000)	[2]
Warrants, Ending balance						[2]		[2]
October 4, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares					$ 0.08	[2]	$ 0.08	[2]
Warrants weighted average life (Years)					0 years	[2]	0 years	[2]
Warrants, Beginning balance		[2]		[2]	5,016,000	[2]	5,016,000	[2]
Warrants, granted						[2]		[2]
Warrants, exercised					(3,425,000)	[2]	(3,425,000)	[2]
Warrants, Expired/Cancelled					(1,591,000)	[2]	(1,591,000)	[2]
Warrants, Ending balance						[2]		[2]
November 30, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares					$ 0.08	[2]	$ 0.08	[2]
Warrants weighted average life (Years)					0 years	[2]	0 years	[2]
Warrants, Beginning balance		[2]		[2]	6,169,926	[2]	6,169,926	[2]
Warrants, granted						[2]		[2]
Warrants, exercised					(3,091,383)	[2]	(3,091,383)	[2]
Warrants, Expired/Cancelled					(3,078,543)	[2]	(3,078,543)	[2]
Warrants, Ending balance						[2]		[2]
January 23, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares					$ 0.08	[2]	$ 0.08	[2]
Warrants weighted average life (Years)					0 years	[2]	0 years	[2]
Warrants, Beginning balance		[2]		[2]	6,388,435	[2]	6,388,435	[2]
Warrants, granted						[2]		[2]
Warrants, exercised					(3,409,160)	[2]	(3,409,160)	[2]
Warrants, Expired/Cancelled					(2,979,275)	[2]	(2,979,275)	[2]
Warrants, Ending balance						[2]		[2]
March 29, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares					$ 0.08	[2]	$ 0.08	[2]
Warrants weighted average life (Years)					0 years	[2]	0 years	[2]
Warrants, Beginning balance		[2]		[2]	8,188,046	[2]	8,188,046	[2]
Warrants, granted						[2]		[2]
Warrants, exercised					(4,496,710)	[2]	(4,496,710)	[2]
Warrants, Expired/Cancelled					(3,691,336)	[2]	(3,691,336)	[2]
Warrants, Ending balance						[2]		[2]
May 13, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercise price | $ / shares					$ 0.08	[2]	$ 0.08	[2]
Warrants weighted average life (Years)					0 years	[2]	0 years	[2]
Warrants, Beginning balance		[2]		[2]	31,404,738	[2]	31,404,738	[2]
Warrants, granted						[2]		[2]
Warrants, exercised					(18,050,408)	[2]	(18,050,408)	[2]
Warrants, Expired/Cancelled					(13,354,330)	[2]	(13,354,330)	[2]
Warrants, Ending balance						[2]		[2]
[1]	The Company received approval of the TSX-V on January 13, 2021 and amended the expiry date of 3,643,791
[2]	On December 20, 2019, the Company exercised its right to call, subject to acceleration provisions, all outstanding warrants set to expire between May 7, 2020 and May 13, 2021. The expiry was amended to January 19, 2020. This expiry date was then extended to February 19, 2020. Any unexercised warrants were voided and of no value after February 19, 2020.

SUMMARY OF CHANGES IN COMMON _2

SUMMARY OF CHANGES IN COMMON SHARE PURCHASE WARRANTS (Details) (Parenthetical)	Nov. 03, 2021$ / shares	Oct. 31, 2021$ / shares	Jan. 13, 2021Days$ / sharesshares	Oct. 31, 2020$ / shares
Equity [Abstract]
Class of Warrant or Right, Outstanding | shares			3,643,791
Common Stock, Par or Stated Value Per Share | (per share)	$ 0.65	$ 0.001	$ 0.30	$ 0.001
Number of minimum consecutive trading days | Days			10

SCHEDULE OF ASSUMPTIONS USED (D

SCHEDULE OF ASSUMPTIONS USED (Details) - $ / shares	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Risk-free interest rates, minimum	0.20%	0.43%
Risk-free interest rates, maximum	1.07%	1.51%
Expected life of options		5 years
Expected annualized volatility	130.88%	120.13%
Expected annualized volatility	140.05%	188.46%
Expected dividend rate
Minimum [Member]
Expected life of options	2 years
Exercise price of options	$ 0.13	$ 0.11
Maximum [Member]
Expected life of options	5 years
Exercise price of options	$ 0.70	$ 0.16

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)	12 Months Ended
	Oct. 31, 2021USD ($)$ / sharesshares	Oct. 31, 2020USD ($)$ / sharesshares	Oct. 31, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding as at October 31, 2020	28,420,000	29,630,000
Granted	38,800,000	6,600,000
Exercised	(2,630,000)	(500,000)
Expired/Cancelled	(3,330,000)	(7,310,000)
Ending balance		28,420,000
Options vested	60,797,500	27,420,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	3,330,000	7,310,000
Weighted average remaining life, outstanding	3 years 5 months 15 days	3 years 2 months 4 days
Weighted average exercise price, beginning balance | $ / shares	$ 0.09	$ 0.07
Weighted average exercise price, granted | $ / shares	0.46	0.13
Weighted average exercise price, exercised | $ / shares	0.07	0.07
Weighted average exercise price, expired/cancelled | $ / shares	0.09	0.07
Weighted average exercise price, ending balance | $ / shares	0.33	0.09
Weighted average exercise price, vested | $ / shares	$ 0.32	$ 0.09
Aggregate intrinsic value, outstanding | $	$ 19,994,025	$ 801,922
Aggregate intrinsic value, vested | $	$ 19,908,026	$ 866,441
Weighted average remaining life, vested	3 years 5 months 15 days	3 years 2 months 4 days
Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Feb. 11, 2021	May 31, 2020
Outstanding as at October 31, 2020	28,420,000
Ending balance	61,260,000	28,420,000
Option One [Member] | February 11, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			$ 0.05
Outstanding as at October 31, 2020	800,000
Granted
Exercised
Expired/Cancelled	(800,000)
Ending balance		800,000
Options vested
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	800,000
Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Aug. 16, 2021	Jun. 3, 2020
Option Two [Member] | August 16, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.05
Outstanding as at October 31, 2020	600,000
Granted
Exercised	(600,000)
Expired/Cancelled
Ending balance		600,000
Options vested
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Mar. 27, 2022	Feb. 11, 2021
Option Three [Member] | March 27, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.05
Outstanding as at October 31, 2020	1,750,000
Granted
Exercised	(250,000)
Expired/Cancelled
Ending balance	1,500,000	1,750,000
Options vested	1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Weighted average remaining life, outstanding	4 months 24 days
Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Aug. 26, 2022	Aug. 16, 2021
Option Four [Member] | August 26, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.13
Outstanding as at October 31, 2020	500,000
Granted
Exercised
Expired/Cancelled	(500,000)
Ending balance		500,000
Options vested
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	500,000
Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Dec. 30, 2022	Mar. 27, 2022
Option Five [Member] | December 30, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.13
Outstanding as at October 31, 2020
Granted	6,150,000
Exercised	(100,000)
Expired/Cancelled	(50,000)
Ending balance	6,000,000
Options vested	5,837,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	50,000
Weighted average remaining life, outstanding	1 year 1 month 28 days
Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Apr. 19, 2023	Aug. 26, 2022
Option Six [Member] | April 19, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.05
Outstanding as at October 31, 2020	800,000
Granted
Exercised
Expired/Cancelled	(800,000)
Ending balance		800,000
Options vested
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	800,000
Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Aug. 12, 2023	Apr. 19, 2023
Option Seven [Member] | August 12, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.05
Outstanding as at October 31, 2020	3,120,000
Granted
Exercised	(600,000)
Expired/Cancelled	(230,000)
Ending balance	2,290,000	3,120,000
Options vested	2,290,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	230,000
Weighted average remaining life, outstanding	1 year 9 months 10 days
Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Dec. 3, 2023	Aug. 12, 2023
Option Eight [Member] | December 3, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.05
Outstanding as at October 31, 2020	7,000,000
Granted
Exercised	(550,000)
Expired/Cancelled
Ending balance	6,450,000	7,000,000
Options vested	6,450,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Weighted average remaining life, outstanding	2 years 1 month 2 days
Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	May 22, 2024	Dec. 3, 2023
Option Nine [Member] | May 22, 2024 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.12
Outstanding as at October 31, 2020	7,950,000
Granted
Exercised
Expired/Cancelled	(50,000)
Ending balance	7,900,000	7,950,000
Options vested	7,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	50,000
Weighted average remaining life, outstanding	2 years 6 months 21 days
Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Nov. 3, 2024	May 22, 2024
Option Ten [Member] | November 3, 2024 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.15
Outstanding as at October 31, 2020	700,000
Granted
Exercised
Expired/Cancelled
Ending balance	700,000	700,000
Options vested	700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Weighted average remaining life, outstanding	3 years 3 days
Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Nov. 24, 2024	Nov. 3, 2024
Option Eleven [Member] | November 24, 2024 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.16
Outstanding as at October 31, 2020	900,000
Granted
Exercised	(30,000)
Expired/Cancelled	(550,000)
Ending balance	320,000	900,000
Options vested	320,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	550,000
Weighted average remaining life, outstanding	3 years 25 days
Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Mar. 26, 2025	Nov. 24, 2024
Option Twelve [Member] | March 26, 2025 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.11
Outstanding as at October 31, 2020	300,000
Granted
Exercised	(200,000)
Expired/Cancelled
Ending balance	100,000	300,000
Options vested	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Weighted average remaining life, outstanding	3 years 4 months 24 days
Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Apr. 23, 2025	Mar. 26, 2025
Option Thirteen [Member] | April 23, 2025 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.12
Outstanding as at October 31, 2020	4,000,000
Granted
Exercised	(300,000)
Expired/Cancelled	(350,000)
Ending balance	3,350,000	4,000,000
Options vested	3,350,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	350,000
Weighted average remaining life, outstanding	3 years 5 months 23 days
Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Dec. 30, 2025	Apr. 23, 2025
Option Fourteen [Member] | December 30, 2025 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.13
Outstanding as at October 31, 2020
Granted	9,500,000
Exercised
Expired/Cancelled
Ending balance	9,500,000
Options vested	9,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Weighted average remaining life, outstanding	4 years 2 months 1 day
Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Aug. 30, 2026
Option Fifteen [Member] | August 30, 2026 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			0.70
Outstanding as at October 31, 2020
Granted	21,700,000
Exercised
Expired/Cancelled
Ending balance	21,700,000
Options vested	21,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Weighted average remaining life, outstanding	4 years 9 months 29 days
Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry Date	Oct. 1, 2026
Option Sixteen [Member] | October 1, 2026 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares			$ 0.50
Outstanding as at October 31, 2020
Granted	1,450,000
Exercised
Expired/Cancelled
Ending balance	1,450,000
Options vested	1,450,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Weighted average remaining life, outstanding	4 years 11 months 1 day

SCHEDULE OF NONVESTED STOCK OPT

SCHEDULE OF NONVESTED STOCK OPTIONS (Details)	12 Months Ended
	Oct. 31, 2021USD ($)$ / sharesshares	Oct. 31, 2021$ / shares	Oct. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares		$ 0.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance	950,000
Share based compensation arrangement by share based payment award options vested number of shares	487,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance	462,500		950,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance | $ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | $ / shares		0.07
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value | $ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance | $ / shares		0.39
Share based Compensation Arrangement By Share based Payment Award Options Weighted AverageGrant Date Fair Value | $
Share based compensation arrangement by share based payment award options grants weighted average grant date fair value | $	170,781
Share based compensation arrangement by sharebased payment award options vested weightedaverage grant date fair value total | $	$ 26,650
hare based compensation arrangement by sharebased payment award options nonvested options forfeited weighted average grant date fair value total | $ / shares
Sshare based compensation arrangement by share based payment award options nonvested weighted average grant date fair value total | $	$ 144,131
December 30, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date	Dec. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares		0.07
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance
Share based compensation arrangement by share based payment award options nonvested grantsin period gross	650,000
Share based compensation arrangement by share based payment award options vested number of shares	487,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance	162,500
Share based Compensation Arrangement By Share based Payment Award Options Outstanding Nonvested Weighted Average Remaining Contractual Term	1 year 1 month 28 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares
August 30, 2026 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Non vested Expiration Date	Aug. 30, 2026
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares		$ 0.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance
Share based compensation arrangement by share based payment award options nonvested grantsin period gross	300,000
Share based compensation arrangement by share based payment award options vested number of shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance	300,000
Share based Compensation Arrangement By Share based Payment Award Options Outstanding Nonvested Weighted Average Remaining Contractual Term	4 years 9 months 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares

SHARE CAPITAL (Details Narrativ

SHARE CAPITAL (Details Narrative)	Nov. 03, 2021USD ($)$ / sharesshares	Oct. 18, 2021USD ($)	Oct. 01, 2021$ / sharesshares	Aug. 30, 2021$ / sharesshares	Aug. 11, 2021USD ($)$ / sharesshares	Aug. 11, 2021CAD ($)shares	Jul. 16, 2021USD ($)shares	Jul. 16, 2021CAD ($)$ / sharesshares	Jun. 17, 2021USD ($)shares	Jun. 17, 2021CAD ($)$ / sharesshares	May 28, 2021USD ($)shares	May 28, 2021CAD ($)$ / sharesshares	May 18, 2021shares	May 05, 2021CAD ($)$ / shares	Apr. 27, 2021USD ($)shares	Apr. 27, 2021CAD ($)$ / sharesshares	Mar. 24, 2021USD ($)shares	Mar. 24, 2021CAD ($)$ / sharesshares	Jan. 29, 2021USD ($)shares	Jan. 29, 2021CAD ($)$ / sharesshares	Jan. 15, 2021USD ($)shares	Jan. 15, 2021CAD ($)shares	Dec. 30, 2020$ / sharesshares	Nov. 20, 2020USD ($)shares	Nov. 20, 2020CAD ($)$ / sharesshares	Sep. 10, 2020CAD ($)$ / sharesshares	May 26, 2020USD ($)shares	May 26, 2020CAD ($)shares	Feb. 19, 2020$ / sharesshares	Jan. 17, 2020USD ($)shares	Jan. 17, 2020CAD ($)shares	Aug. 08, 2018	Jun. 17, 2021USD ($)	Apr. 27, 2021USD ($)shares	Apr. 27, 2021CAD ($)$ / sharesshares	Oct. 31, 2021USD ($)$ / sharesshares	Oct. 31, 2021CAD ($)$ / sharesshares	Oct. 31, 2020USD ($)$ / sharesshares	Oct. 31, 2020USD ($)$ / shares$ / sharesshares	Oct. 31, 2022$ / sharesshares	Nov. 03, 2021CAD ($)$ / sharesshares	Oct. 31, 2021CAD ($)$ / sharesshares	Aug. 11, 2021$ / shares	Jul. 15, 2021USD ($)	Jul. 15, 2021CAD ($)$ / shares	Jun. 11, 2021shares	Jun. 07, 2021USD ($)shares	Jun. 07, 2021CAD ($)$ / sharesshares	Apr. 24, 2021$ / shares	Mar. 11, 2021CAD ($)	Jan. 15, 2021$ / shares	Jan. 13, 2021$ / shares	Oct. 31, 2020CAD ($)$ / sharesshares	Jan. 17, 2020CAD ($)$ / shares	Aug. 28, 2018USD ($)	Nov. 01, 2016$ / shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common voting shares																																				1,000,000,000		1,000,000,000	1,000,000,000			1,000,000,000											1,000,000,000
Common stock par value | (per share)																																				$ 0.001		$ 0.001	$ 0.001		$ 0.65											$ 0.30
Warrants expire date																																				Feb. 19, 2020						Feb. 19, 2020
Common stock warrants exercised																													35,472,661
Exercise of warrants price per share | $ / shares																													$ 0.08													$ 0.05
Common stock warrants exercised																																				4,864,000						4,864,000
Common shares price per share | $ / shares																																																								$ 0.05
Common stock subscriptions received | $																																				$ 209,827		$ 596,872	$ 596,872
Common stock shares issued																											500,000	500,000
Proceeds from stock options erercised																											$ 26,401	$ 37,000
Conversion of equity reserves to share capital amount | $																											$ 19,775
Common stock shares issued	9,163,425												1,360,959																							392,943,398		323,419,527	323,419,527		9,163,425	392,943,398					1,538,461	1,538,461					323,419,527
Convertiable common shares													263,973
Conversion of stock value | $		$ 26,286
Fair value of assets	$ 4,796,832																																								$ 5,956,226						$ 305,832	$ 369,231		$ 5,956,226
Proceeds from stock warrants erercised																																				$ 887,520	$ 1,120,130
Common stock warrants expired unexercised																																				525,173						525,173
Number of stock options granted																																				38,800,000	38,800,000	6,600,000
Issued and outstanding common shares value | $																																				$ 29,842,167		$ 21,322,022	$ 21,322,022
Shares available for grant																																				5,892,368						5,892,368
Stock-based compensation | $																																				$ 11,051,124		$ 666,259
Weighted average grant date fair value | $ / shares																																					$ 0.22
Outstanding as at October 31, 2020																																				28,420,000	28,420,000	29,630,000		28,420,000
Stock issued during period shares stock options exercised																																				(2,630,000)	(2,630,000)	(500,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																				(3,330,000)	(3,330,000)	(7,310,000)
Ending balance																																						28,420,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																				60,797,500		27,420,000	27,420,000			60,797,500											27,420,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																				3 years 5 months 15 days	3 years 5 months 15 days	3 years 2 months 4 days
Weighted average exercise price, beginning balance | $ / shares	$ 0.33																																				$ 0.09		$ 0.07	$ 0.09
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares																																					0.46		0.13
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares																																					0.07		0.07
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $ / shares																																					0.09		0.07
Weighted average exercise price, ending balance | $ / shares																																					0.33		0.09
Weighted average exercise price, vested | $ / shares																																					$ 0.32		$ 0.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $																																				$ 19,994,025		$ 801,922	$ 801,922
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $																																				$ 19,908,026		$ 866,441	$ 866,441
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																																				3 years 5 months 15 days	3 years 5 months 15 days	3 years 2 months 4 days
Intrinsic value of options exercised | $																																				$ 962,936		$ 28,533
Debt Instrument, Face Amount | $																																				$ 53,491
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount																																				120,808,982	120,808,982	38,529,642
July 2021 Convertible Debenture [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of warrants price per share | $ / shares																																													$ 0.20
Debt Instrument, Face Amount																																				$ 79,542						$ 100,000		$ 79,542	$ 100,000
Option One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Feb. 11, 2021	Feb. 11, 2021	May 31, 2020
Outstanding as at October 31, 2020	61,260,000																																			28,420,000	28,420,000			28,420,000
Ending balance																																				61,260,000	61,260,000	28,420,000
Option Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Aug. 16, 2021	Aug. 16, 2021	Jun. 3, 2020
Option Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Mar. 27, 2022	Mar. 27, 2022	Feb. 11, 2021
Option Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Aug. 26, 2022	Aug. 26, 2022	Aug. 16, 2021
Option Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Dec. 30, 2022	Dec. 30, 2022	Mar. 27, 2022
Option Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Apr. 19, 2023	Apr. 19, 2023	Aug. 26, 2022
Option Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Aug. 12, 2023	Aug. 12, 2023	Apr. 19, 2023
Option Eight [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Dec. 3, 2023	Dec. 3, 2023	Aug. 12, 2023
Option Nine [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				May 22, 2024	May 22, 2024	Dec. 3, 2023
Option Ten [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Nov. 3, 2024	Nov. 3, 2024	May 22, 2024
Option Eleven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Nov. 24, 2024	Nov. 24, 2024	Nov. 3, 2024
Option Twelve [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Mar. 26, 2025	Mar. 26, 2025	Nov. 24, 2024
Option Thirteen [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Apr. 23, 2025	Apr. 23, 2025	Mar. 26, 2025
Option Fourteen [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Dec. 30, 2025	Dec. 30, 2025	Apr. 23, 2025
Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average grant date fair value | $ / shares																																					$ 0.36		$ 0.14
May 31, 2020 [Member] | Option One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.08
Outstanding as at October 31, 2020																																						400,000
Stock issued during period shares stock options exercised																																				(400,000)	(400,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Ending balance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
June Three Two Thousand Twenty [Member] | Option Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.05
Outstanding as at October 31, 2020																																						550,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																						(550,000)
Ending balance
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
February 11, 2021 [Member] | Option Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.05
Outstanding as at October 31, 2020																																				800,000	800,000	1,300,000		800,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																						(500,000)
Ending balance																																						800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						800,000	800,000														800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						6 months 10 days
August 16, 2021 [Member] | Option Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.05
Outstanding as at October 31, 2020																																				600,000	600,000	1,200,000		600,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																						(600,000)
Ending balance																																						600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						600,000	600,000														600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						1 year 14 days
March 27, 2022 [Member] | Option Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.05
Outstanding as at October 31, 2020																																				1,750,000	1,750,000	2,000,000		1,750,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																						(250,000)
Ending balance																																						1,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						1,750,000	1,750,000														1,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						1 year 7 months 24 days
August 26, 2022 [Member] | Option Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted																																						500,000
Share Price | $ / shares																																																					$ 0.13
Outstanding as at October 31, 2020																																				500,000	500,000			500,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Ending balance																																						500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
April 19, 2023 [Member] | Option Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.05
Outstanding as at October 31, 2020																																				800,000	800,000	800,000		800,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Ending balance																																						800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						800,000	800,000														800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						2 years 8 months 19 days
August 12, 2023 [Member] | Option Eight [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.05
Outstanding as at October 31, 2020																																				3,120,000	3,120,000	3,780,000		3,120,000
Stock issued during period shares stock options exercised																																				(100,000)	(100,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																						(560,000)
Ending balance																																						3,120,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						3,120,000	3,120,000														3,120,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						3 years 10 days
December 3, 2023 [Member] | Option Nine [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.05
Outstanding as at October 31, 2020																																				7,000,000	7,000,000	9,600,000		7,000,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																						(2,600,000)
Ending balance																																						7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						7,000,000	7,000,000														7,000,000
December 3, 2023 [Member] | Option Ten [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						3 years 4 months 6 days
May 22, 2024 [Member] | Option Ten [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted
Share Price | $ / shares																																																					$ 0.12
Outstanding as at October 31, 2020																																				7,950,000	7,950,000	10,000,000		7,950,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																						(2,050,000)
Ending balance																																						7,950,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						7,950,000	7,950,000														7,950,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						3 years 9 months 21 days
November 3, 2024 [Member] | Option Eleven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted																																						700,000
Share Price | $ / shares																																																					$ 0.15
Outstanding as at October 31, 2020																																				700,000	700,000			700,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Ending balance																																						700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						700,000	700,000														700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						4 years 3 months 7 days
November 24, 2024 [Member] | Option Twelve [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted																																						900,000
Share Price | $ / shares																																																					$ 0.16
Outstanding as at October 31, 2020																																				900,000	900,000			900,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Ending balance																																						900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						775,000	775,000														775,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						4 years 3 months 25 days
March 26, 2025 [Member] | Option Thirteen [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted																																						300,000
Share Price | $ / shares																																																					$ 0.11
Outstanding as at October 31, 2020																																				300,000	300,000			300,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Ending balance																																						300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						300,000	300,000														300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						4 years 7 months 28 days
April 23, 2025 [Member] | Option Fourteen [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted																																						4,200,000
Share Price | $ / shares																																																					$ 0.12
Outstanding as at October 31, 2020																																				4,000,000	4,000,000			4,000,000
Stock issued during period shares stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period																																						(200,000)
Ending balance																																						4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number																																						3,625,000	3,625,000														3,625,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																																						4 years 8 months 23 days
2017 Stock Option Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted																							15,650,000															6,600,000
Stock option granted terms																																Stock options granted are subject to a maximum term of 5 years. All options granted shall vest immediately, except for those options granted to persons performing investor relations activities for the Company.
Options exercisable price | $ / shares																							$ 0.13
2017 Stock Option Plan [Member] | Exercisable at Five Years [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options exercisable																							9,500,000
2017 Stock Option Plan [Member] | Exercisable at Two Years [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options exercisable																							6,150,000
2021 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock options granted			1,450,000	21,700,000
Number of shares authorized to issued																																														27,312,368
Number of stock options forfeited																																				1,730,000	1,730,000
Options exercisable price | $ / shares			$ 0.50	$ 0.70
Options exercisable period			5 years	5 years
Shares available for grant																																				29,042,368						29,042,368
Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from stock options erercised																																				$ 140,734	$ 175,800
Conversion of equity reserves to share capital amount | $																																				$ 121,932
Number of stock options granted																																				2,630,000	2,630,000
Maximum [Member] | 2017 Stock Option Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage of authorized grant stock options																																20.00%
Options exercisable price | $ / shares																																																					$ 0.16
Options exercisable period																																						5 years
Maximum [Member] | Director and Officers [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Percentage of ownership of common stock																																																							5.00%
Issued and outstanding common shares value | $																																																							$ 5,000,000
Maximum [Member] | Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of options price per share | $ / shares																																								$ 0.16
Minimum [Member] | 2017 Stock Option Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options exercisable price | $ / shares																																																					$ 0.11
Options exercisable period																																						2 years
Minimum [Member] | Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of options price per share | $ / shares																																					$ 0.05
Non Brokered Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued					3,827,601	3,827,601	4,350,000	4,350,000	23,076,926	23,076,926																				3,643,792	3,643,792			25,724,955	25,724,955
Common shares price per share | (per share)					$ 0.44			$ 0.20						$ 0.13		$ 0.13										$ 0.13									$ 0.13								$ 0.55											$ 0.15
Proceeds from issuance of private placement					$ 1,683,336	$ 2,105,180	$ 690,860	$ 870,000		$ 3,000,000																				$ 416,719	$ 546,569		$ 2,442,531	$ 2,621,314	$ 3,344,244
Common stock subscriptions received																														$ 39,722								$ 596,872	$ 596,872														$ 747,392	$ 52,922
Issuance of shares, description					Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 (US$0.52) for a period of eighteen months from the date of closing.	Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.65 (US$0.52) for a period of eighteen months from the date of closing.	Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing.	Each unit consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.30 for a period of one year from the date of closing.	Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche.	Each unit issued consists of one common share and one common share purchase warrant entitling the holder thereof to acquire a further common share at a price of CA$0.19 for a period of one year from the date of closing of the respective financing tranche.																Each unit is comprised of one common share and one common share purchase warrant exercisable at CA$0.19 per common share for a period of one year.				Each unit consists of one common share and one common share purchase warrant exercisable at a price of CA$0.21 per common share for a period of one year. The expiration date of these common share purchase warrants was subsequently extended to August 31, 2021. These common share purchase warrants were subject to an expiry acceleration provision, upon thirty days’ written notice, should the price of the Company’s common shares exceed CA$0.30 for at least ten consecutive trading days.	Each unit consists of one common share and one common share purchase warrant exercisable at a price of CA$0.21 per common share for a period of one year. The expiration date of these common share purchase warrants was subsequently extended to August 31, 2021. These common share purchase warrants were subject to an expiry acceleration provision, upon thirty days’ written notice, should the price of the Company’s common shares exceed CA$0.30 for at least ten consecutive trading days.			Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche.	Each unit issued consists of one common share and one common share purchase warrant entitling the holder to acquire a further common share at a price of CA$0.19 for a period of one year from the closing date of the respective financing tranche.
Finders fees paid | $																														$ 41,275
Shares issuance costs | $					$ 116,479		$ 48,319		$ 154,336						$ 195,614
Non Brokered Private Placement [Member] | Share-based Payment Arrangement, Tranche One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued											5,223,420	5,223,420												5,599,171	5,599,171
Common shares price per share | $ / shares												$ 0.13													$ 0.13
Proceeds from issuance of private placement											$ 561,844	$ 679,044												$ 556,876	$ 727,892
Non Brokered Private Placement [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																					7,337,914	7,337,914
Common shares price per share | $ / shares																																																			$ 0.13
Proceeds from issuance of private placement																					$ 749,435	$ 953,930
Common stock subscriptions received | $																					$ 39,996
Non Brokered Private Placement [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																			5,382,303	5,382,303
Common shares price per share | $ / shares																				$ 0.13
Proceeds from issuance of private placement																			$ 547,496	$ 699,699
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																	6,554,172	6,554,172
Common shares price per share | $ / shares																		$ 0.13
Proceeds from issuance of private placement																	$ 678,270	$ 852,042
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Five and Final [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued															851,395	851,395
Common shares price per share | $ / shares										$ 0.13																																							$ 0.13
Proceeds from issuance of private placement															$ 89,237	$ 110,681
Non Brokered Private Placement [Member] | Share Based Compensation Award Tranche Two And Final [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued									17,853,506	17,853,506
Common shares price per share | $ / shares										$ 0.13
Proceeds from issuance of private placement									$ 1,880,687	$ 2,320,956
Non Brokered Private Placement [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																										53,846,154
Proceeds from issuance of private placement | $														$ 3,000,000												$ 7,000,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock warrants expired unexercised																													24,794,484
Conversion of equity reserves to share capital amount | $																																				$ 4,291
Common stock shares issued																																				7,014,969						7,014,969
Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of warrants price per share | $ / shares																																										$ 0.21
Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise of warrants price per share | $ / shares																																										$ 0.05
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																																				56,979,482	56,979,482	3,643,791
Common shares price per share | $ / shares																																									$ 0.65							$ 0.24
Common stock shares issued																																				2,630,000	2,630,000	500,000

CAPITAL MANAGEMENT (Details Nar

CAPITAL MANAGEMENT (Details Narrative) - USD ($)	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2019
Capital Management
Stockholders deficit	$ 6,770,038	$ 2,079,903	$ 1,269,030

SCHEDULE OF CLASSIFICATION OF I

SCHEDULE OF CLASSIFICATION OF ITS FINANCIAL INSTRUMENTS (Details)	Oct. 31, 2021USD ($)
Fair Value Disclosures [Abstract]
Cash	$ 462,360
Amounts receivable	151,485
Deposits held by related parties	486,462
Accounts payable and accrued liabilities	1,989,316
Due to related parties	1,026,817
Convertible debenture	107
Convertible debenture and derivative liability	$ 7,449,700

SCHEDULE OF FOREIGN CURRENCY RI

SCHEDULE OF FOREIGN CURRENCY RISK (Details)	Oct. 31, 2021USD ($)
Total	$ (2,067,422)
Cash [Member]
Assets	186,627
Deposits Held By Related Parties [Member]
Assets	486,462
Accounts Payable and Accrued Liabilities [Member]
Liabilities	(773,011)
Due To Related Parties [Member]
Liabilities	(467,500)
Convertible Debenture [Member]
Liabilities	$ (1,500,000)

FINANCIAL INSTRUMENTS AND FIN_3

FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Fair Value Disclosures [Abstract]
Cash	$ 462,360	$ 39,571
Short term investments	0	0
Foreign currency risk rate
Increase decrease in foreign currency transaction amount	262,941
Working capital deficit	$ 9,657,316	$ 2,392,189

SCHEDULE OF ASSETS INFORMATION

SCHEDULE OF ASSETS INFORMATION (Details) - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment	$ 2,574,704	$ 79,436
Mineral property costs	93,453	93,453
Property, plant, equipment and mineral properties	2,668,157	172,889
Other assets	1,845,355	535,874
Total Assets	4,513,512	708,763
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment	2,546,383	79,436
Other assets	1,554,827	533,815
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment	28,321
Mineral property costs	93,453	93,453
Other assets	$ 290,528	$ 2,059

SCHEDULE OF EFFECTIVE TAX RATES

SCHEDULE OF EFFECTIVE TAX RATES RECONCILIATION (Details) - USD ($)	12 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Loss for the year	$ (23,549,612)	$ (4,672,605)
Statutory rate	33.02%	31.21%
Expected income tax recovery at statutory rate	$ (7,778,880)	$ (1,458,320)
Net adjustment for deductible and non-deductible amounts	2,636,262	250,196
Foreign exchange effect	(9,867)	(175,597)
Valuation allowance	5,152,485	1,383,721
Deferred income tax provision (recovery)

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITY (Details) - USD ($)	Oct. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Non-capital loss carry-forwards	$ 5,340,578	$ 2,600,561
Property and equipment	(159,673)	(123,561)
Lease liability	180,812	103,789
Convertible debenture	(509,985)
Convertible debenture – derivative liability	2,532,898
Exploration and evaluation asset	359,700
Share issue costs		11,056
Valuation allowance	(7,744,330)	(2,591,845)
Deferred income tax asset (liability)

INCOME TAX (Details Narrative)

INCOME TAX (Details Narrative) - USD ($)	Oct. 31, 2021	Oct. 30, 2021
UNITED KINGDOM
Net operating loss	$ 13,439,000	$ 3,515,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	Jan. 20, 2022$ / sharesshares	Dec. 13, 2021$ / sharesshares	Dec. 03, 2021$ / sharesshares	Nov. 26, 2021USD ($)$ / sharesshares	Nov. 04, 2021$ / sharesshares	Nov. 03, 2021USD ($)shares	Nov. 03, 2021CAD ($)$ / sharesshares	Oct. 01, 2021$ / sharesshares	Aug. 30, 2021$ / sharesshares	Feb. 10, 2022CAD ($)$ / sharesshares	Oct. 31, 2021USD ($)shares	Oct. 31, 2020USD ($)shares	Oct. 31, 2021$ / shares	Jun. 07, 2021$ / shares	Feb. 08, 2021shares	Feb. 19, 2020$ / shares	Aug. 28, 2018USD ($)	Nov. 01, 2016$ / shares
Subsequent Event [Line Items]
Number of shares issued price per share | $ / shares																		$ 0.05
Proceeds from issuance of common stock | $											$ 7,328,389	$ 2,715,129
Capital stock Authorized: 1 billion common stock at par value of $0.001 Issued and paid: 392,943,398 (2020 – 323,419,527) | $											29,842,167	21,322,022
Stock issued during period, value | $											$ 6,841,169	$ 376,997
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 0.05			$ 0.08
Incentive stock options granted											38,800,000	6,600,000
2021 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Incentive stock options granted								1,450,000	21,700,000
Options exercisable price | $ / shares								$ 0.50	$ 0.70
Options exercisable term								5 years	5 years
Maximum [Member]
Subsequent Event [Line Items]
Warrants exercisable															33,000,000
Common Stock [Member]
Subsequent Event [Line Items]
Stock issued during period, shares											56,979,482	3,643,791
Number of shares issued price per share | $ / shares							$ 0.65							$ 0.24
Stock issued during period, value | $											$ 7,438,041	$ 416,719
Stock issued during period, conversion shares											1,360,959
Common Stock [Member] | Agreement [Member]
Subsequent Event [Line Items]
Common stock issued and outstanding percentage																	5.00%
Common Stock [Member] | Agreement [Member] | Maximum [Member]
Subsequent Event [Line Items]
Capital stock Authorized: 1 billion common stock at par value of $0.001 Issued and paid: 392,943,398 (2020 – 323,419,527) | $																	$ 5,000,000
Warrant [Member] | Maximum [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 0.21
Subsequent Event [Member] | 2021 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Incentive stock options granted			250,000
Options exercisable price | $ / shares			$ 0.58
Options exercisable term			5 years
Subsequent Event [Member] | Class A Warrants [Member]
Subsequent Event [Line Items]
Warrants exercisable	500,000	500,000			500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.13	$ 0.13			$ 0.13
Subsequent Event [Member] | Class B Warrants [Member]
Subsequent Event [Line Items]
Warrants exercisable	500,000	500,000			500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.19	$ 0.19			$ 0.19
Subsequent Event [Member] | June 2021 Convertible Debentures [Member]
Subsequent Event [Line Items]
Stock issued during period, conversion units	1,000,000	1,000,000			1,000,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock issued during period, shares						9,163,425	9,163,425			15,159,448
Number of shares issued price per share | $ / shares							$ 0.65			$ 0.19
Proceeds from issuance of common stock | $										$ 2,880,295
Stock issued during period, value						$ 4,796,832	$ 5,956,226
Stock issued during period, conversion shares	1,000,000	1,000,000			1,000,000
Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Stock issued during period, shares				1,375,499
Number of shares issued price per share | $ / shares				$ 0.55
Proceeds from issuance of private placement | $				$ 756,524
Share price | $ / shares				$ 0.75
Subsequent Event [Member] | Common Stock One [Member]
Subsequent Event [Line Items]
Stock issued during period, shares										200,000
Number of shares issued price per share | $ / shares										$ 0.05
Proceeds from issuance of common stock | $										$ 10,000
Subsequent Event [Member] | Common Stock Two [Member]
Subsequent Event [Line Items]
Stock issued during period, shares										30,000
Number of shares issued price per share | $ / shares										$ 0.30
Proceeds from issuance of common stock | $										$ 9,000
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Warrants unexercised										2,428,363